Mitigating single point failure of devices in an analyte monitoring system and methods thereof

Information

  • Patent Grant
  • 12364419
  • Patent Number
    12,364,419
  • Date Filed
    Friday, February 19, 2021
    4 years ago
  • Date Issued
    Tuesday, July 22, 2025
    a day ago
Abstract
Methods, devices, and kits are provided for mitigating single point failure of at least one device in an analyte monitoring system.
Description
BACKGROUND

The detection of the level of glucose or other analytes, such as lactate, oxygen or the like, in certain individuals is vitally important to their health. For example, the monitoring of glucose is particularly important to individuals with diabetes. Diabetics may need to monitor glucose levels to determine when insulin is needed to reduce glucose levels in their bodies or when additional glucose is needed to raise the level of glucose in their bodies.


Devices have been developed for continuous or automatic monitoring of analytes, such as glucose, in bodily fluid such as in the blood stream or in interstitial fluid. Some of these analyte measuring devices are configured so that at least a portion of the devices are positioned below a skin surface of a user, e.g., in a blood vessel or in the subcutaneous tissue of a user.


SUMMARY

Embodiments of the present disclosure include methods for mitigating single point failure of at least one device in an analyte monitoring system. Certain aspects include requesting that a functionality check of one or more components of a first device be performed and that data related to the functionality check of the one or more components of the first device be communicated to a second device, receiving, information from the first device that is related to functionality of the one or more components of the first device, communicating the information related to the functionality of the one or more components of the first device to a third device, receiving a request from the third device that an alarm be annunciated if it is determined by the third device that the one or more components of the first device is not functioning in accordance with at least one predetermined criterion and annunciating an alarm to alert a user that the one or more components of the first device is not functioning in accordance with the at least one predetermined criterion.


Embodiments of the present disclosure include computer-implemented methods for mitigating single point failure of at least one device in an analyte monitoring. Certain aspects include requesting that a functionality check of one or more components of a first device be performed and that data related to the functionality check of the one or more components of the first device be communicated to a second device, receiving the data related to the functionality of the one or more components of the first device, retrieving a list including at least one predetermined criterion related to the functionality of the one or more components of the first device from a storage component of the second device, comparing the data related to the functionality of the one or more components of the first device with the list including the at least one predetermined criterion and determining if the one or more components of the first device is functioning in accordance with the at least one predetermined criterion.


Embodiments of the present disclosure include computer-implemented methods for mitigating single point failure of at least one device in an analyte monitoring. Certain aspects include requesting that a functionality check of one or more components of a first device be performed and that data related to the functionality check of the one or more components of the first device be communicated to a second device and determining that the one or more components of the first device is not functioning properly if the data related to the functionality check of the components of the first device is not received at the second device, wherein an alarm is annunciated from at least one of the second device or a third device to alert a user that one or more components of the first device is not functioning properly.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system in accordance with certain embodiments of the present disclosure;



FIG. 2 illustrates a data monitoring and management system for real time glucose measurement data acquisition and processing in one aspect of the present disclosure;



FIG. 3 is a block diagram of a receiver/monitor unit such as that shown in FIG. 1 in accordance with certain embodiments;



FIG. 4 is a flowchart illustrating a method for mitigating single point failure of at least one device in an analyte monitoring system in accordance with certain embodiments of the present disclosure;



FIG. 5 is a flowchart illustrating a method for mitigating single point failure of at least one device in an analyte monitoring system in accordance with certain embodiments of the present disclosure;



FIG. 6 is a flowchart illustrating a method for mitigating single point failure of at least one device in an analyte monitoring system in accordance with certain embodiments of the present disclosure; and



FIG. 7 is a flowchart illustrating a method for mitigating single point failure of at least one device in an analyte monitoring system in accordance with certain embodiments of the present disclosure.





DETAILED DESCRIPTION

Before the present disclosure is further described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.


As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.


Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, exemplary methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.


As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.



FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system in accordance with certain embodiments of the present disclosure. Embodiments of the subject disclosure are described primarily with respect to glucose monitoring devices and systems, and methods of using two or more devices in a glucose monitoring system to reduce the likelihood of a failure of one or more of the devices in the glucose monitoring system going unnoticed by a user.


Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.


Referring to FIG. 1, the analyte monitoring system 100 includes a sensor 101, a data processing unit (e.g., sensor electronics) 102 connectable to the sensor 101, and a primary receiver unit 104 which is configured to communicate with the data processing unit 102 via a communication link 103. In aspects of the present disclosure, the sensor 101 and the data processing unit (sensor electronics) 102 may be configured as a single integrated assembly 110. In certain embodiments, the integrated sensor and sensor electronics assembly 110 may be configured as an on-body patch device. In such embodiments, the on-body patch device may be configured for, for example, RFID or RF communication with a reader device/receiver unit, and/or an insulin pump.


In certain embodiments, the primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 to evaluate or otherwise process or format data received by the primary receiver unit 104. The data processing terminal 105 may be configured to receive data directly from the data processing unit 102 via a communication link which may optionally be configured for bi-directional communication. Further, the data processing unit 102 may include a transmitter or a transceiver to transmit and/or receive data to and/or from the primary receiver unit 104, the data processing terminal 105 or optionally the secondary receiver unit 106.


Also shown in FIG. 1 is an optional secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the data processing unit 102. The secondary receiver unit 106 may be configured to communicate with the primary receiver unit 104, as well as the data processing terminal 105. The secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105. As discussed in further detail below, in certain embodiments the secondary receiver unit 106 may be a de-featured receiver as compared to the primary receiver unit 104, i.e., the secondary receiver unit 106 may include a limited or minimal number of functions and features as compared with the primary receiver unit 104. As such, the secondary receiver unit 106 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device such as a wrist watch, arm band, etc., for example. Alternatively, the secondary receiver unit 106 may be configured with the same or substantially similar functions and features as the primary receiver unit 104. The secondary receiver unit 106 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or bi-directional communication device.


Only one sensor 101, data processing unit 102 and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in FIG. 1. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include more than one sensor 101 and/or more than one data processing unit 102, and/or more than one data processing terminal 105.


The analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within the analyte monitoring system 100. For example, unique IDs, communication channels, and the like, may be used.


In certain embodiments, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to at least periodically perform a functionality check and convert the results of the functionality check into a corresponding signal for transmission by the data processing unit 102.


The data processing unit 102 is coupleable to the sensor 101 so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously. The data processing unit 102 in certain embodiments may include a portion of the sensor 101 (proximal section of the sensor in electrical communication with the data processing unit 102) which is encapsulated within or on the printed circuit board of the data processing unit 102 with, for example, potting material or other protective material. The data processing unit 102 performs data processing functions, where such functions may include but are not limited to, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103. In one embodiment, the sensor 101 or the data processing unit 102 or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user.


In one aspect, the primary receiver unit 104 may include an analog interface section including an RF receiver and an antenna that is configured to communicate with the data processing unit 102 via the communication link 103, and a data processing section for processing the received data from the data processing unit 102 such as data decoding, error detection and correction, data clock generation, and/or data bit recovery.


In operation, the primary receiver unit 104 in certain embodiments is configured to synchronize with the data processing unit 102 to uniquely identify the data processing unit 102, based on, for example, an identification information of the data processing unit 102, and thereafter, to periodically receive signals transmitted from the data processing unit 102 associated with the monitored analyte levels detected by the sensor 101. That is, when operating in the CGM mode, the receiver unit 104 in certain embodiments is configured to automatically receive data related to the functionality of the sensor from the analyte sensor/sensor electronics when the communication link (e.g., RF range) is maintained between these components.


Referring again to FIG. 1, the data processing terminal 105 may include a personal computer, a portable data processing devices or computers such as a laptop computer or a handheld device (e.g., personal digital assistants (PDAs), communication devices such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone, a Blackberry device, a Palm device such as Palm Pre, Treo, or similar phone), mp3 player, pager, and the like), drug delivery device, insulin pump, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown).


The data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the primary receiver unit 104 for receiving, among others, the measured analyte level. Alternatively, the primary receiver unit 104 may be configured to integrate an infusion device therein so that the primary receiver unit 104 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the data processing unit 102. An infusion device may be an external device or an internal device (wholly implantable in a user).


In particular embodiments, the data processing terminal 105, which may include an insulin pump, may be configured to receive the functionality signals from the data processing unit 102, and thus, incorporate the functions of the primary receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring. In certain embodiments, the communication link 103 as well as one or more of the other communication interfaces shown in FIG. 1 may use one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements) while avoiding potential data collision and interference.


As described in aspects of the present disclosure, the analyte monitoring system may include an on-body patch device with a thin profile that can be worn on the arm or other locations on the body (and under clothing worn by the user or the patient), the on-body patch device including an analyte sensor and circuitry and components for operating the sensor and processing and storing signals, including functionality signals, received from the sensor as well as for communication with the reader device. For example, one aspect of the on-body patch device may include electronics to sample the voltage signal received from the analyte sensor in fluid contact with the body fluid, and to process the sampled voltage signals into the corresponding glucose values and/or store the sampled voltage signal as raw data, or to perform a functionality check of its components, and to process the results of the functionality check into a signal or data.


In certain embodiments, the on-body patch device includes an antenna such as a loop antenna to receive RF power from an external device such as the reader device/receiver unit described above, electronics to convert the RF power received via the antenna into DC (direct current) power for the on-body patch device circuitry, communication module or electronics to detect commands received from the reader device, and communication component to transmit data to the reader device, a low capacity battery for providing power to sensor sampling circuitry (for example, the analog front end circuitry of the on-body patch device in signal communication with the analyte sensor), one or more non-volatile memory or storage device to store data including raw signals from the sensor or processed data based on the raw sensor signals. More specifically, in the on operation demand mode, the on-body patch device in certain embodiments is configured to transmit real time analyte related data and/or stored historical analyte related data, and/or functionality data when within the RF power range of the reader device. As such, when the reader device is removed or positioned out of range relative to the on-body patch device, the on-body patch device may no longer transmit the analyte related data and/or functionality data.


In certain embodiments, a data processing module/terminal may be provided in the analyte monitoring system that is configured to operate as a data logger, interacting or communicating with the on-body patch device by, for example, transmitting requests for functionality information to the on-body patch device, and storing the responsive functionality information received from the on-body patch device in one or more memory components of the data processing module (e.g., repeater unit). Further, data processing module may be configured as a compact on-body relay device to relay or retransmit the received analyte level information from the on-body patch device to the reader device/receiver unit or the remote terminal or both. The data processing module in one aspect may be physically coupled to the on-body patch device, for example, on a single adhesive patch on the skin surface of the patient. Alternatively, the data processing module may be positioned close to but not in contact with the on-body patch device. For example, when the on-body patch device is positioned on the abdomen of the patient, the data processing module may be worn on a belt of the patient or the user, such that the desired close proximity or predetermined distance of approximately 1-5 inches (or about 1-10 inches, for example, or more) between the on-body patch device and the data processing module may be maintained.


The various processes described above including the processes operating in the software application execution environment in the analyte monitoring system including the on-body patch device, the reader device, data processing module and/or the remote terminal performing one or more routines described above may be embodied as computer programs developed using an object oriented language that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships. The software required to carry out the inventive process, which may be stored in a memory or storage device of the storage unit of the various components of the analyte monitoring system described above in conjunction to the Figures including the on-body patch device, the reader device, the data processing module, various described communication devices, or the remote terminal may be developed by a person of ordinary skill in the art and may include one or more computer program products.


In one embodiment, an apparatus for bi-directional communication with an analyte monitoring system may comprise a storage device having stored therein one or more routines, a processing unit operatively coupled to the storage device and configured to retrieve the stored one or more routines for execution, a data transmission component operatively coupled to the processing unit and configured to transmit data based at least in part on the one or more routines executed by the processing unit, and a data reception component operatively coupled to the processing unit and configured to receive functionality related data from a remote location and to store the received functionality related data in the storage device for retransmission, wherein the data transmission component is programmed to transmit a query to a remote location, and further wherein the data reception component receives the functionality related data from the remote location in response to the transmitted query when one or more electronics in the remote location transitions from an inactive state to an active state upon detection of the query from the data transmission component.



FIG. 2 illustrates a data monitoring and management system for functionality related data acquisition and processing in one aspect of the present disclosure. More specifically, as shown in FIG. 2, the on-body patch device 211 including sensor electronics coupled to an analyte sensor 250 is positioned on a skin surface 210 of a patient or a user.


Referring back to FIG. 2, as shown, when the reader device/receiver unit 220 is positioned or placed in close proximity and within a predetermined range of the on-body patch device 211, the RF power supply in the reader device/receiver unit 220 may be configured to provide the necessary power to operate the electronics in the on-body patch device 211, and the on-body patch device 211 may be configured to, upon detection of the RF power from the reader device/receiver unit 220, perform preprogrammed routines including, for example, transmitting one or more signals 240 to the reader device/receiver unit 220 indicative of the functionality of the components of the analyte sensor 250, or performing functionality check of one or more components of the analyte sensor 250.


In certain embodiments, the reader device/receiver unit 220 may include an RF power switch that is user activatable or activated upon positioning within a predetermined distance from the on-body patch device 211 to turn on the analyte sensor in the on-body patch device 211. That is, using the RF signal, the analyte sensor coupled to the sensor electronics in the on-body patch device 211 may be initialized or activated. In another embodiment, a passive RFID function may be provided or programmed such that upon receiving a “turn on” signal which, when authenticated, will turn on the electronic power switch that activates the on-body patch device 211. That is, the passive RFID configuration may include drawing energy from the RF field radiated from the reader device/receiver unit 220 so as to prompt for and/or detect the “turn on” signal which, upon authentication, activates the on-body patch device 211.


In one embodiment, communication and/or RF power transfer between the reader device/receiver unit 220 and the on-body patch device 211 may be automatically initiated when the reader device/receiver unit 220 is placed in close proximity to the on-body patch device 211 as discussed above. Alternatively, the reader device/receiver unit 220 may be configured such that user activation, such as data request initiation and subsequent confirmation by the user using, for example, the display 222 and/or input components 221 of the reader device/receiver unit 220, may be required prior to the initiation of communication and/or RF power transfer between the reader device/receiver unit 220 and the on-body patch device 211. In a further embodiment, the reader device/receiver unit 220 may be user configurable between multiple modes, such that the user may choose whether the communication between the reader device/receiver unit 220 and on-body patch device 211 is performed automatically or requires a user activation and/or confirmation.


As further shown in FIG. 2, the display 222 of the reader device/receiver unit 220 may be configured to provide the functionalities of a user interface to present information such as alarm or alert notification to the user. In one aspect, the reader device/receiver unit 220 may include other output components such as a speaker, vibratory output component and the like to provide audible and/or vibratory output indication to the user in addition to the visual output indication provided on the display 222.


As discussed, some or all of the electronics in the on-body patch device 211 in one embodiment may be configured to rely on the RF power received from the reader device/receiver unit 220 to perform functionality data processing and/or transmission of the processed functionality information to the reader device/receiver unit 220. That is, the on-body patch device 211 may be discreetly worn on the body of the user or the patient, and under clothing, for example, and when desired, by positioning the reader device/receiver unit 220 within a predetermined distance from the on-body patch device 211, functionality information may be received by the reader device/receiver unit 220.


Referring still to FIG. 2, also shown are a data processing module/terminal 260 and a remote terminal 270. In one aspect, data processing module 260 may include a stand alone device configured for bi-directional communication to communicate with the on-body patch device 211, the reader device/receiver unit 220 and/or the remote terminal 270. More specifically, data processing module 260 may include one or more microprocessors or similar data processing components configured to execute one or more software routines for communication, as well as data storage and retrieval to and from one or more memory components provided in the housing of the data processing module 260.


The data processing module 260 in one embodiment may be configured to communicate with the on-body patch device 211 in a similar manner as the reader device/receiver unit 220 and may include communication components such as antenna, power supply and memory, among others, for example, to allow provision of RF power to the on-body patch device 211 or to request or prompt the on-body patch device 211 to send the functionality related data and optionally stored analyte related data. The data processing module 260 may be configured to interact with the on-body patch device 211 in a similar manner as the reader device/receiver unit 220 such that the data processing module 260 may be positioned within a predetermined distance from the on-body patch device 211 for communication with the on-body patch device 211.


In one aspect, the on-body patch device 211 and the data processing module 260 may be positioned on the skin surface of the user or the patient within the predetermined distance of each other (for example, within approximately 5 inches or less) such that the communication between the on-body patch device 211 and the data processing module 260 is maintained. In a further aspect, the housing of the data processing module 260 may be configured to couple to or cooperate with the housing of the on-body patch device 211 such that the two devices are combined or integrated as a single assembly and positioned on the skin surface.


Referring again to FIG. 2, the data processing module 260 may be configured or programmed to prompt or ping the on-body patch device 211 at a predetermined time interval such as once every minute, or once every five minutes or once every 30 minutes or any other suitable or desired programmable time interval to request functionality related data from the on-body patch device 211 which is received and is stored in one or more memory devices or components of the data processing module 260. In another embodiment, the data processing module 260 is configured to prompt or ping the on-body patch device 211 when desired by the patient or the user on-demand, and not based on a predetermined time interval. In yet another embodiment, the data processing module 260 is configured to prompt or ping the on-body patch device 211 when desired by the patient or the user upon request only after a programmable time interval has elapsed. For example, in certain embodiments, if the user does not initiate communication within a programmed time period, such as, for example 5 hours from last communication (or 10 hours from the last communication), the data processing module 260 may be programmed to automatically ping or prompt the on-body patch device 211 or alternatively, initiate an alarm function to notify the user that an extended period of time has elapsed since the last communication between the data processing module 260 and the on-body patch device 211. In this manner, users, healthcare providers, or the patient may program or configure the data processing module 260 to provide certain compliance with analyte monitoring regimen, to avoid a failure of the analyte sensor device from going unnoticed. Similar functionalities may be provided or programmed in the receiver unit or the reader device in certain embodiments.


As further shown in FIG. 2, the data processing module 260 in one aspect may be configured to transmit the stored data received from the on-body patch device 211 to the reader device/receiver unit 220 when communication between the data processing module 260 and the reader device/receiver unit 220 is established. More specifically, in addition to RF antenna and RF communication components described above, data processing module 260 may include components to communicate using one or more wireless communication protocols such as, for example, but not limited to, infrared (IR) protocol, Bluetooth® protocol, Zigbee® protocol, and 802.11 wireless LAN protocol. Additional description of communication protocols including those based on Bluetooth® protocol and/or Zigbee® protocol can be found in U.S. Patent Publication No. 2006/0193375 incorporated herein by reference for all purposes. The data processing module 260 may further include communication ports, drivers or connectors to establish wired communication with one or more of the reader device/receiver unit 220, on-body patch device 211, or the remote terminal 270 including, for example, but not limited to USB connector and/or USB port, Ethernet connector and/or port, FireWire connector and/or port, or RS-232 port and/or connector.


In one aspect, the data processing module 260 may be configured to operate as a data logger configured or programmed to periodically request or prompt the on-body patch device 211 to transmit the functionality related information, and to store the received information for later retrieval or subsequent transmission to the reader device/receiver unit 220 or to the remote terminal 270 or both, for further processing and analysis.


In a further aspect, the functionalities of the data processing module 260 may be configured or incorporated into a memory device such as an SD card, microSD card, compact flash card, XD card, Memory Stick card, Memory Stick Duo card, or USB memory stick/device including software programming resident in such devices to execute upon connection to the respective one or more of the on-body patch device 211, the remote terminal 270 or the reader device/receiver unit 220. In a further aspect, the functionalities of the data processing module 260, including executable software and programming, may be provided to a communication device such as a mobile telephone including, for example, iPhone, iPod Touch, Blackberry device, Palm based device (such as Palm Pre, Treo, Treo Pro, Centro), personal digital assistants (PDAs) or any other communication enabled operating system (such as Windows or Android operating systems) based mobile telephones as a downloadable application for execution by the downloading communication device. To this end, the remote terminal 270 as shown in FIG. 2 may include a personal computer, or a server terminal that is configured to provide the executable application software to one or more of the communication devices described above when communication between the remote terminal 270 and the devices are established.


Depending upon the user setting or configuration on the communication device, the downloaded application may be programmed or customized using the user interface of the respective communication device (screen, keypad, and the like) to establish or program the desired settings such as a receiver alarm, an insulin pump alarm, sensor replacement alarm, or any other alarm or alert conditions as may be desired by the user. Moreover, the programmed notification settings on the communication device may be output using the output components of the respective communication devices, such as speaker, vibratory output component, or visual output/display. As a further example, the communication device may be provided with programming and application software to communicate with the on-body patch device 211 such that a frequency or periodicity of data acquisition is established. In this manner, the communication device may be configured to conveniently receive functionality information from the on-body patch device 211 at predetermined time periods such as, for example, but not limited to once every minute, once every five minutes, or once every 10 or 15 minutes, and store the received information, as well as to provide a desired or appropriate warning indication or notification to the user or the patient.



FIG. 3 is a block diagram of a receiver/monitor unit or insulin pump such as that shown in FIG. 1 in accordance with certain embodiments. The primary receiver unit 104 (FIG. 1) includes one or more of: a blood glucose test strip interface 301, an RF receiver 302, an input 303, a temperature detection section 304, and a clock 305, each of which is operatively coupled to a processing and storage section 307. The primary receiver unit 104 also includes a power supply 306 operatively coupled to a power conversion and monitoring section 308. Further, the power conversion and monitoring section 308 is also coupled to the receiver processor 307. Moreover, also shown are a receiver serial communication section 309, and an output 310, each operatively coupled to the processing and storage unit 307. The receiver may include user input and/or interface components or may be free of user input and/or interface components.


In one aspect, the RF receiver 302 is configured to communicate, via the communication link 103 (FIG. 1) with the data processing unit (sensor electronics) 102, to receive encoded data from the data processing unit 102 for, among others, signal mixing, demodulation, and other data processing. The input 303 of the primary receiver unit 104 is configured to allow the user to enter information into the primary receiver unit 104 as needed. In one aspect, the input 303 may include keys of a keypad, a touch-sensitive screen, and/or a voice-activated input command unit, and the like. The temperature monitor section 304 may be configured to provide temperature information of the primary receiver unit 104 to the processing and control section 307, while the clock 305 provides, among others, real time or clock information to the processing and storage section 307.


Each of the various components of the primary receiver unit 104 shown in FIG. 3 is powered by the power supply 306 (or other power supply) which, in certain embodiments, includes a battery. Furthermore, the power conversion and monitoring section 308 is configured to monitor the power usage by the various components in the primary receiver unit 104 for effective power management and may alert the user, for example, in the event of power usage which renders the primary receiver unit 104 in sub-optimal operating conditions. The serial communication section 309 in the primary receiver unit 104 is configured to provide a bi-directional communication path from the testing and/or manufacturing equipment for, among others, initialization, testing, and configuration of the primary receiver unit 104.


Serial communication section 309 can also be used to upload data to a computer, such as functionality related data. The communication link with an external device (not shown) can be made, for example, by cable (such as USB or serial cable), infrared (IR) or RF link. The output/display 310 of the primary receiver unit 104 is configured to provide, among others, a graphical user interface (GUI), and may include a liquid crystal display (LCD) for displaying information. Additionally, the output/display 310 may also include an integrated speaker for outputting audible signals as well as to provide vibration output as commonly found in handheld electronic devices, such as mobile telephones, pagers, etc. In certain embodiments, the primary receiver unit 104 also includes an electro-luminescent lamp configured to provide backlighting to the output 310 for output visual display in dark ambient surroundings.


Referring back to FIG. 3, the primary receiver unit 104 may also include a storage section such as a programmable, non-volatile memory device as part of the processor 307, or provided separately in the primary receiver unit 104, operatively coupled to the processor 307. The processor 307 may be configured to perform Manchester decoding (or other protocol(s)) as well as error detection and correction upon the encoded data received from the data processing unit 102 via the communication link 103.


In further embodiments, the data processing unit 102 and/or the primary receiver unit 104 and/or the secondary receiver unit 106, and/or the data processing terminal/infusion section 105 of FIG. 1 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a blood glucose meter. In further embodiments, a user manipulating or using the analyte monitoring system 100 (FIG. 1) may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, voice commands, and the like) incorporated in the one or more of the data processing unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105.


Additional detailed descriptions are provided in U.S. Pat. Nos. 5,262,035; 5,264,104; 5,262,305; 5,320,715; 5,593,852; 6,175,752; 6,650,471; 6,746, 582; 6,284,478; 7,299,082; and 7,811,231; in U.S. application Ser. No. 11/060,365 filed Feb. 16, 2005 titled “Method and System for Providing Data Communication in Continuous Glucose Monitoring And Management System”, now U.S. Pat. No. 8,771,183, in U.S. application Ser. No. 12/698,124 filed Feb. 1, 2010 titled “Compact On-Body Physiological Monitoring Devices and Methods Thereof”, and in U.S. application Ser. No. 12/807,278 filed Aug. 31, 2010 titled “Medical Devices and Methods”, now U.S. Pat. No. 10,136,816, each of which is incorporated herein by reference.


A safety issue with the receiver device, continuous glucose monitors (CGMs), repeater unit, and insulin pumps in an analyte monitoring system is the susceptibility to single point failure associated with each device's microprocessor, power supply, audio annunciators, transmitter, and transceiver. Introducing a power supply monitoring circuit, a microprocessor monitoring circuit, a secondary power supply, and/or audio annunciator (or vibrator) to the device will provide redundancy that will reduce the likelihood of a failure going unnoticed by the user; however, including these components is costly in terms of expense and product size. The embodiments of the present disclosure provide additional protection against single point failures in systems made up of two or more devices. Essentially, each device in the analyte monitoring system is monitored by one or more of the other devices in the system.


In certain integrated CGM and insulin pump system embodiments, where both devices contain at least one microprocessor, power supply, and audio annunciator or other alarm mechanism, in one embodiment, each device can perform a periodic self test and report this to the other device. Each device has a monitoring process that would initiate an alarm if the other device does not report a successful self test. In some embodiments, the monitoring device could poll the other device, and even initiate the self test on the other device. Also, different functionality could be tested and/or reported on different test schedules.


The applicability of this functionality depends on how necessary periodic communication between the devices is to the function of the system. For instance, in certain embodiments where the receiver device of a continuous analyte monitoring system may not need to be in communication, such as RF communication, range with an insulin pump for the insulin pump to function, this feature could be optional, e.g., configured by the user, a parent of the user, and/or a physician. In other embodiments, such as for a closed loop control system where the control algorithm is maintained in the receiver device, frequent communication is needed between the handheld and the pump, and therefore continuous knowledge of the functionality of both devices is vital.



FIG. 4 is a flow diagram illustrating steps in an embodiment for mitigating single point failure of at least one device in an analyte monitoring system 400. The first device 402 and the second device 404 in the analyte monitoring system 400 can be at least one of a receiver device, an analyte meter, a glucose monitor, an insulin pump, a continuous analyte monitor, a cellular phone, a personal digital assistant, a personal computer, a laptop computer, and/or a repeater unit. In certain embodiments, a first device 402 sends a request that a functionality check of the components of a second device 404 be performed (406). The request can be sent, for example, wirelessly from the transmitter of the first device 402 to the transceiver of the second device 404. The components of the second device 404 can include at least one of a microprocessor, a power supply, a sensor, an electronic component, and a storage device.


The second device 404 receives the request to perform a functionality check of the second device 404 from the first device 402 (408) and performs the functionality check of its components (410). In certain embodiments, the second device 404 only performs the functionality check if the second device 404 has the capacity to perform the check. A functionality check, or “self-test”, is a standard feature of most electronic devices. The functionality check of the components can include a determination of the current, voltage, and/or resistance that can be measured across an electrical circuit in the one or more components. The functionality check can include component testing that applies an input to the various components being tested, and receives an output based on the input. The functionality check may also include checking digital system components, such as a checksum for a block of memory. Any of a number of common techniques used in electronic devices can be applied to the functionality check of the present disclosure. In addition, some components of the devices in the analyte monitoring system may have built in self-test functionality that can be queried. For instance, a power supply module may have a digital self-test status output that can be queried by the processor in order to determine the functionality of the power supply. A device may have electronic circuitry that includes electronic or mechanical switches that allow testing of the electronic circuitry. The switch, for example, could route the current path for functional test across the speaker circuit to test for the proper speaker resistance, in order to detect any open or short circuits.


Referring still to FIG. 4, the second device 404 determines the functionality of its components based on the outcome of the functionality check (412) and the second device 404 communicates data related to the determined functionality of its components to the first device 402 (414). In certain embodiments the second device 404 determining the functionality of its components (412) is optional and data related to the functionality of the second device 404 can be sent to the first device 402 without a determination of functionality being processed at the second device 404. The data can be communicated, for example, from the transmitter of the second device 404 to the transceiver of the first device 402.


Still referring to FIG. 4, the data related to the functionality of the components of the second device 404 is received at the first device 402 (416). The first device 402 then retrieves from storage a list that includes at least one predetermined criterion related to the functionality of the components of the second device 404 (418). The predetermined criterion can be, for instance, current, voltage and/or resistance thresholds or ranges used to define the proper operating range. In certain embodiments, for example, the functional check may measure the power supply voltage to determine if it is in an acceptable tolerance. In certain embodiments, the predetermined criterion may be a digital or coded threshold range used to define the proper operating range, whereby, the measured functional test output can be compared to the criterion threshold (e.g., above or below) or compared to the criterion range (e.g., within or outside) to determine functional test status of the component.


Returning to FIG. 4, the first device 402 compares the data related to the functionality of the second device 404 with the list including the at least one predetermined criterion (420) to determine if the second device 404 is functioning properly (422). In certain embodiments, the first device 402 annunciates or otherwise communicates an alarm to alert a user if it is determined that the second device 404 is not functioning properly (424). The alarm may be at least one of an audio alarm, a vibratory alarm, and a visual alarm.


In certain embodiments, the first device 402 does not have to poll the second device 404 to perform the functionality check if the second device 404 automatically performs the functionality check at predetermined intervals and automatically sends a signal or data related to the functionality of the second device 404 to the first device 402. In this manner, in certain embodiments, if the first device 402 does not automatically receive a signal or data related to the functionality of the second device 404 within a predetermined time period, then the first device 402 will annunciate an alarm to alert the user that the second device 404 is not functioning properly.



FIG. 5 is a flow diagram illustrating steps in an embodiment for mitigating single point failure of at least one device in an analyte monitoring system 500. The first device 502 and the second device 504 in the analyte monitoring system 500 can be at least one of a receiver device, an analyte meter, a glucose monitor, an insulin pump, a continuous analyte monitor, a cellular phone, a personal digital assistant, a personal computer, a laptop computer, and/or a repeater unit. Execution of the method begins at process block (506) when a first device 502 sends a request that a functionality check of the components of a second device 504 be performed. The request can be sent, for example, wirelessly from the transmitter of the first device 502 to the transceiver of the second device 504. The components of the second device 504 include at least one of a microprocessor, a power supply, a sensor, an electronic component, and a storage device.


Referring to FIG. 5, the second device 504 receives the request to perform a functionality check from the first device 502 (508) and the second device 504 performs the functionality check of its components (510). In certain embodiments, the second device 504 only performs the functionality check if the second device 504 has the capacity to perform the check. The functionality check of the components can include a determination of the current, voltage, and/or resistance that can be measured across an electrical circuit in the components. Additionally, the functionality check can include component testing that applies an input to the various components being tested, and receives an output based on the input. The functionality check may also include checking digital system components, such as a checksum for a block of memory. Any of a number of common techniques used in electronic devices can be applied to this invention. In addition, some components of the devices in the analyte monitoring system may have built in self-test functionality that can be queried, for instance, a power supply module may have a digital self-test status output that can be queried by the processor in order to determine the functionality of the power supply. Also, a device may have electronic circuitry that includes electronic or mechanical switches that allow testing of the electronic circuitry. The switch, for example, could route the current path for functional test across the speaker circuit to test for the proper speaker resistance, in order to detect any open or short circuits.


Referring back to FIG. 5, the second device 504 determines the functionality of its components based on the outcome of the functionality check (512) and communicates data related to the determined functionality of its components to the first device 502 (514). The data can be communicated, for example, from the transmitter of the second device 504 to the transceiver of the first device 502. In certain embodiments, the second device 504 may communicate data related to the functionality of its components to the first device 502 without determining the functionality of the components at the second device 504 itself. The data related to the functionality of the components of the second device 504 is then received at the first device 502 (516) and the first device 502 retrieves from storage a list that includes at least one predetermined criterion related to the functionality of the components of the second device 504 (518). The predetermined criterion can be, for instance, current, voltage and/or resistance thresholds or ranges used to define the proper operating range. In certain embodiments, the functional check may measure the power supply voltage to determine if it is in an acceptable tolerance. In certain embodiments, the predetermined criterion may be a digital or coded threshold range used to define the proper operating range. The measured functional test output can be compared to the criterion threshold (e.g., above or below) or compared to the criterion range (e.g., within or outside) to determine functional test status of the component.


Referring still to FIG. 5, the first device 502 compares the data related to the functionality of the second device 504 with the list including the at least one predetermined criterion at process block (520) and determines if the second device 504 is functioning properly (522). If it is determined that the second device 504 is not functioning properly, the first device 502 requests that the second device 504 annunciate an alarm to alert a user that the second device 504 is not functioning properly (524). The request may be sent from the transmitter of the first device 502 to the transceiver of the second device 504. The second device 504 receives the request from the first device 502 to annunciate the alarm to alert the user of its lack of proper functionality (526) and then annunciates the corresponding alarm (528). The alarm may be at least one of an audio alarm, a vibratory alarm, and a visual alarm.



FIG. 6 is a flow diagram illustrating steps in one embodiment for mitigating single point failure of at least one device in an analyte monitoring system 600 that includes a first device 602, a repeater unit 604, and a second device 606. The first device 602 can include at least one of a receiver unit, an analyte meter, a cellular phone, a personal digital assistant, a personal computer, a laptop computer, and an insulin pump. The repeater unit 604 can be operatively or physically coupled to second device 606. The second device can be an analyte sensor and/or a continuous glucose monitor.


Referring to FIG. 6, in certain embodiments, the first device 602 sends a request to the repeater unit 604 that the second device 606 perform a functionality check of its components (608). The request can be sent, for example, wirelessly from the transmitter of the first device 602 to the transceiver of the repeater unit 604. The repeater unit 604 receives the request from the first device 602 (610) and sends, to the second device 606, a request to perform a functionality check of the components of the second device 606 (612). The request may be sent, for example, wirelessly from the transmitter of the repeater unit 604 to the transceiver of the second device 606.


Still referring to FIG. 6, the request to perform a functionality check of its components is received at the second device 606 (614) and, if it is functioning in a high enough capacity, the second device 606 performs the functionality check of one or more of its components (616). In certain embodiments, the functionality check of the components can include a determination of the current, voltage, and/or resistance that can be measured across an electrical circuit in the one or more components. Additionally, the functionality check can include component testing that applies an input to the various components being tested, and receives an output based on the input. The functionality check may also include checking digital system components, such as a checksum for a block of memory. Any of a number of common techniques used in electronic devices can be applied to this invention. In addition, some components of the devices in the analyte monitoring system may have built in self-test functionality that can be queried, for instance, a power supply module may have a digital self-test status output that can be queried by the processor in order to determine the functionality of the power supply. Also, a device may have electronic circuitry that includes electronic or mechanical switches that allow testing of the electronic circuitry. The switch, for example, could route the current path for functional test across the speaker circuit to test for the proper speaker resistance, in order to detect any open or short circuits.


Returning to FIG. 6, the second device 606 determines the functionality check of its components based upon the results of the functionality check (618) and data related to the results of the functionality check are then communicated from the second device 606 to the repeater unit 604 (620). The data can be communicated, for example, wirelessly from the transmitter of the second device 606 to the transceiver of the repeater unit 604. The repeater unit 604 receives the data related to the results of the functionality check of the one or more components of the second device 606 (622) and communicates the data related to the results of the functionality check of the second device 606 to the first device 602 (624). The data can be communicated, for example, wirelessly from the transmitter of the repeater unit 604 to the transceiver of the first device 602. The data related to the functionality check of the one or more components of the second device 606 is then received at the first device 602 (626). The first device 602 retrieves from storage a list including at least one predetermined criterion related to the functionality of the one or more components of the second device (628) and compares the data related to the results of the functionality check with the list including the at least one predetermined criterion (630). The predetermined criterion can be, for instance, current, voltage and/or resistance thresholds or ranges used to define the proper operating range. For instance, the functional check may measure the power supply voltage to determine if it is in an acceptable tolerance. Additionally, the predetermined criterion may be a digital or coded threshold range used to define the proper operating range. The measured functional test output can be compared to the criterion threshold (e.g., above or below) or compared to the criterion range (e.g., within or outside) to determine functional test status of the component. The first device 602 then determines if the second device 604 is functioning in accordance with the at least one predetermined criterion (632) and, if it is determined that the second device 606 is not functioning in accordance with the at least one predetermined criterion, requests that the repeater unit 604 annunciate an alarm (634). The request can be sent, for example, from the transmitter of the first device 602 to the transceiver of the repeater unit 604. The repeater unit 604 receives the request from the first device 602 to annunciate an alarm to alert a user that the second device 606 is not functioning properly (636) and accordingly an alarm is annunciated by the repeater unit 604 (638). The alarm may include at least one of an audio alarm, a vibratory alarm, and a visual alarm that is produced at the repeater unit 604.


In certain embodiments, the first device 602 does not have to send a request to the repeater unit 604 if the repeater unit 604 automatically polls the second device 606 to perform the functionality check or if the second device 606 automatically performs the functionality check at predetermined intervals and then automatically sends this information to the repeater unit 604. In this instance, if the repeater unit 604 does not receive a signal or data related to the functionality of the second device 606, then the repeater unit 604 can annunciate an alarm to alert the user that the second device 606 is not functioning properly.



FIG. 7 is a flow diagram illustrating an embodiment for mitigating single point failure of the transmitter of at least one device in an analyte monitoring system 700 that includes a first device 702 and a second device 704. The first device 702 sends a request to a second device 704 to perform a functionality check of the components of the second device 704 (706). If a signal or data has not been received at the first device 702 within a predetermined amount of time, then the first device 702 determines that at least one of the components of the second device 704 is not functioning properly (710) and annunciates an alarm to alert a user that the second device 704 is not functioning properly (712).


In certain embodiments, the first device 702 does not have to request that the second device 704 perform a functionality check of its components, as the second device 704 automatically performs the functionality check at predetermined intervals and then automatically sends data related to the results of the functionality check to the first device 702. In this instance, if the first device 702 does not automatically receive data related to the functionality of the second device 704, then the first device 702 determines that the second device 704 is not functioning properly and annunciates an alarm at the first device 702 to alert the user.


In certain embodiments, the analyte monitoring system includes at least one transmitter attached to the continuous analyte sensor, the receiver device, and the insulin pump. In certain embodiments, the receiver device and/or the insulin pump will detect if the transmitter in the continuous analyte sensor stops functioning. In certain embodiments, the insulin pump and/or the continuous analyte sensor will detect if the transmitter in the receiver device stops functioning. In certain embodiments, the receiver device and/or the continuous analyte sensor will detect if the transmitter in the insulin pump stops functioning.


In certain embodiments, a computer-implemented method for mitigating single point failure of at least one device in an analyte monitoring system includes requesting that a functionality check of one or more components of a first device be performed and that data related to the functionality check of the one or more components of the first device be communicated to a second device, receiving information from the first device that is related to functionality of the one or more components of the first device, communicating the information related to the functionality of the one or more components of the first device to a third device, receiving a request from the third device that an alarm be annunciated if it is determined by the third device that the one or more components of the first device is not functioning in accordance with at least one predetermined criterion, and annunciating an alarm to alert a user that the one or more components of the first device is not functioning in accordance with the at least one predetermined criterion.


In certain aspects, the first device is a continuous glucose monitor.


In certain aspects, the second device includes a repeater unit operatively coupled to the continuous glucose monitor.


In certain aspects, the third device includes one of a receiver device or an insulin pump.


In certain aspects, the one or more components of the first device include at least one of a microprocessor, a power supply, a sensor, and an electronic component.


In certain aspects, the alarm includes at least one of an audio alarm, a vibratory alarm, and a visual alarm.


Certain aspects include receiving a request from the third device that a functionality check of one or more components of a first device be performed and that data related to the functionality check of the one or more components of the first device be communicated to the third device, wherein the request is received at the second device, the second device being operatively coupled to the first device.


In certain aspects, the information related to the functionality of the one or more components of the first device includes a lack of data being received from the first device.


Certain aspects include that the functionality check includes at least one of a determination of a current, a voltage, and a resistance that is measured across an electrical circuit in the one or more components, applying an input to the one or more components and receiving an output from the one or more components, a digital check of the one or more components, a checksum of a memory of the first device, a self-test output check of the one or more components, and an electrical or mechanical test of at least one switch of the one or more components.


Certain embodiments include the at least one predetermined criterion including at least one of a current, a voltage, and a resistance threshold used to define a proper operating range of the first device, a power supply measurement that defines an acceptable tolerance, and a digital threshold range used to define a proper operating range.


In certain embodiments, a computer-implemented method for mitigating single point failure of at least one device in an analyte monitoring system includes requesting that a functionality check of one or more components of a first device be performed and that data related to the functionality check of the one or more components of the first device be communicated to a second device, receiving the data related to the functionality of the one or more components of the first device, retrieving a list including at least one predetermined criterion related to the functionality of the one or more components of the first device from a storage component of the second device, comparing the data related to the functionality of the one or more components of the first device with the list including the at least one predetermined criterion, and determining if the one or more components of the first device is functioning in accordance with the at least one predetermined criterion.


Certain aspects include requesting that an alarm be annunciated at a third device to alert a user if it is determined by the second device that the one or more components of the first device is not functioning in accordance with the at least one predetermined criterion.


In certain aspects, the third device is operatively coupled to the first device.


In certain aspects, the request for the functionality check is received by a third device and the third device polls the first device to perform the functionality check.


Certain aspects include annunciating an alarm operatively coupled to the second device to alert a user if it is determined that the one or more components of the first device is not functioning in accordance with the at least one predetermined criterion.


In certain aspects, the first device is a continuous glucose monitor.


In certain aspects, the second device is one of a receiver device or an insulin pump.


In certain aspects, the third device is a repeater unit operatively coupled to the continuous glucose monitor.


In certain aspects, the one or more first components of the first device include at least one of a microprocessor, a power supply, a sensor, and an electric component.


In certain aspects, the alarm includes at least one of an audio alarm, a vibratory alarm, and a visual alarm.


Certain aspects include that the functionality check includes at least one of a determination of a current, a voltage, and a resistance that is measured across an electrical circuit in the one or more components, applying an input to the one or more components and receiving an output from the one or more components, a digital check of the one or more components, a checksum of a memory of the first device, a self-test output check of the one or more components, and an electrical or mechanical test of at least one switch of the one or more components.


Certain aspects include that the at least one predetermined criterion includes at least one of a current, a voltage, and a resistance threshold used to define a proper operating range of the first device, a power supply measurement that defines an acceptable tolerance, and a digital threshold range used to define a proper operating range.


In certain embodiments, a computer-implemented method for mitigating single point failure of at least one device in an analyte monitoring system includes requesting that a functionality check of one or more components of a first device be performed and that data related to the functionality check of the one or more components of the first device be communicated to a second device, and determining that the one or more components of the first device is not functioning properly if the data related to the functionality check of the components of the first device is not received at the second device, wherein an alarm is annunciated from at least one of the second device or a third device to alert a user that one or more components of the first device is not functioning properly.


Various other modifications and alterations in the structure and method of operation of the embodiments of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in connection with certain embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A system for mitigating single point failure comprising: one or more processors; anda memory storing instructions which, when executed by the one or more processors, cause the one or more processors to:transmit, from a first device, a request to perform an operational test of one or more components of a second device, wherein the one or more components relate to sensing an analyte level of a subject;receive from the second device data related to operation of the one or more components of the second device in response to the request; andcause an alarm to be annunciated based on the data related to the operation of the one or more components of the second device.
  • 2. The system of claim 1, wherein the alarm is annunciated by the first device.
  • 3. The system of claim 1, wherein the instructions cause the one or more processors to determine whether the second device is functioning properly based on the data related to the operation of the one or more components.
  • 4. The system of claim 1, wherein the operational test comprises a functionality check of the one or more components of the second device.
  • 5. The system of claim 1, wherein the alarm indicates that the second device is not functioning properly based on the operational test.
  • 6. The system of claim 1, wherein the alarm indicates that the second device is functioning properly based on the operational test.
  • 7. The system of claim 1, wherein the instructions cause the one or more processors to receive the data related to the operation of the one or more components from the second device within a predetermined time period after the operational test is performed.
  • 8. The system of claim 7, wherein the predetermined time period is at least one of 1 minute, 5 minutes, 10 minutes, or 15 minutes.
  • 9. The system of claim 1, wherein the alarm comprises at least one of an audible alarm, vibratory alarm, or a visual alarm.
  • 10. A system for mitigating single point failure comprising: one or more processors; anda memory storing instructions which, when executed by the one or more processors, cause the one or more processors to: receive, from a first device, a request to perform an operational test of one or more components of the second device, wherein the one or more components relate to sensing an analyte level of a subject;perform the operational test to obtain data related to operation of the one or more components of the second device;communicate to the first device the data related to operation of the one or more components of the second device.
  • 11. The system of claim 10, wherein the operational test comprises a digital self-test.
  • 12. The system of claim 11, wherein the one or more components comprises at least one of a block of memory or a power supply module.
  • 13. The system of claim 10, wherein the operational test comprises a functionality check of the one or more components.
  • 14. The system of claim 13, wherein the functionality check comprises a determination of at least one of current, voltage, or resistance measured across an electrical circuit of the one or more components.
  • 15. A method for mitigating single point failure, comprising: transmitting, from a first device, a request to perform an operational test of one or more components of a second device, wherein the one or more components relate to sensing an analyte level of a subject;receiving from the second device data related to operation of the one or more components of the second device in response to the request; andannunciating an alarm based on the data related to the operation of the one or more components of the second device.
  • 16. The method of claim 15, wherein the alarm is annunciated by the first device.
  • 17. The method of claim 15, further comprising: determining whether the second device is functioning properly based on the data related to the operation of the one or more components.
  • 18. The method of claim 15, wherein the operational test comprises a functionality check of the one or more components of the second device.
  • 19. The method of claim 15, wherein the alarm indicates that the second device is not functioning properly based on the operational test of the device.
  • 20. The method of claim 15, wherein the alarm indicates that the second device is functioning properly based on the operational test of the device.
  • 21. The method of claim 15, further comprising: receiving the data related to the operation of the one or more components from the second device within a predetermined time period after the operational test is performed.
  • 22. The method of claim 21, wherein the predetermined time period is at least one of 1 minute, 5 minutes, 10 minutes, or 15 minutes.
  • 23. The method of claim 15, wherein the alarm comprises at least one of an audible alarm, vibratory alarm, or a visual alarm.
  • 24. A system for mitigating single point failure comprising: one or more processors; anda memory storing instructions which, when executed by the one or more processors, cause the one or more processors to:transmit, from a first device, a request to perform a first operational test of one or more components of a second device, wherein the one or more components relate to monitoring an analyte level of a subject, wherein at least one of the components is a power supply module;receive from the second device data related to operation of the one or more components of the second device in response to the request;cause a first alarm to be annunciated based on the data related to the operation of the one or more components of the second device;wherein the first device is configured to perform, at a predetermined time interval, a second operation test of one or more components of the first device;determining that the first device has not transmitted data related to operation of one or more components of the first device in accordance with the predetermined time interval; andcause, in response to the determining, a second alarm to be annunciated.
  • 25. The system of claim 24, wherein the instructions cause the one or more processors to determine whether the second device is functioning properly based on the data related to the operation of the one or more components of the second device.
  • 26. The system of claim 24, wherein the first operational test comprises a functionality check of the one or more components of the second device.
  • 27. The system of claim 24, wherein the instructions cause the one or more processors to receive the data related to the operation of the one or more components of the second device within a predetermined time period after the first operational test is performed.
RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 16/197,253 filed Nov. 20, 2018, which is a continuation of U.S. patent application Ser. No. 15/686,153 filed Aug. 24, 2017, now U.S. Pat. No. 10,136,847, which is a continuation of U.S. patent application Ser. No. 15/016,247, now U.S. Pat. No. 9,743,872, which is a continuation of U.S. patent application Ser. No. 14/251,542 filed Apr. 11, 2014, now U.S. Pat. No. 9,289,179, which is a continuation of U.S. patent application Ser. No. 13/684,078 filed Nov. 21, 2012, now U.S. Pat. No. 8,710,993, which claims priority to U.S. Provisional Application No. 61/563,518, filed Nov. 23, 2011, entitled “Mitigating Single Point Failure of Devices in an Analyte Monitoring System and Methods Thereof”, the disclosures of each of which are incorporated herein by reference in their entirety for all purposes.

US Referenced Citations (1287)
Number Name Date Kind
3581062 Aston May 1971 A
3926760 Allen et al. Dec 1975 A
3949388 Fuller Apr 1976 A
3960497 Acord et al. Jun 1976 A
4033330 Willis et al. Jul 1977 A
4036749 Anderson Jul 1977 A
4055175 Clemens et al. Oct 1977 A
4129128 McFarlane Dec 1978 A
4245634 Albisser et al. Jan 1981 A
4327725 Cortese et al. May 1982 A
4344438 Schultz Aug 1982 A
4349728 Phillips et al. Sep 1982 A
4373527 Fischell Feb 1983 A
4392849 Petre et al. Jul 1983 A
4425920 Bourland et al. Jan 1984 A
4431004 Bessman et al. Feb 1984 A
4441968 Emmer et al. Apr 1984 A
4464170 Clemens et al. Aug 1984 A
4478976 Goertz et al. Oct 1984 A
4494950 Fischell Jan 1985 A
4509531 Ward Apr 1985 A
4527240 Kvitash Jul 1985 A
4538616 Rogoff Sep 1985 A
4619793 Lee Oct 1986 A
4671288 Gough Jun 1987 A
4703756 Gough et al. Nov 1987 A
4731726 Allen, III Mar 1988 A
4749985 Corsberg Jun 1988 A
4757022 Shults et al. Jul 1988 A
4777953 Ash et al. Oct 1988 A
4779618 Mund et al. Oct 1988 A
4847785 Stephens Jul 1989 A
4854322 Ash et al. Aug 1989 A
4871351 Feingold Oct 1989 A
4890620 Gough Jan 1990 A
4925268 Iyer et al. May 1990 A
4953552 DeMarzo Sep 1990 A
4986271 Wilkins Jan 1991 A
4995402 Smith et al. Feb 1991 A
5000180 Kuypers et al. Mar 1991 A
5002054 Ash et al. Mar 1991 A
5019974 Beckers May 1991 A
5050612 Matsumura Sep 1991 A
5051688 Murase et al. Sep 1991 A
5055171 Peck Oct 1991 A
5068536 Rosenthal Nov 1991 A
5082550 Rishpon et al. Jan 1992 A
5106365 Hernandez Apr 1992 A
5122925 Inpyn Jun 1992 A
5135004 Adams et al. Aug 1992 A
5165407 Wilson et al. Nov 1992 A
5202261 Musho et al. Apr 1993 A
5204264 Kaminer et al. Apr 1993 A
5210778 Massart May 1993 A
5228449 Christ et al. Jul 1993 A
5231988 Wernicke et al. Aug 1993 A
5243696 Carr et al. Sep 1993 A
5246867 Lakowicz et al. Sep 1993 A
5251126 Kahn et al. Oct 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5279294 Anderson et al. Jan 1994 A
5285792 Sjoquist et al. Feb 1994 A
5293877 O'Hara et al. Mar 1994 A
5298144 Spokane Mar 1994 A
5299571 Mastrototaro Apr 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5330634 Wong et al. Jul 1994 A
5340722 Wolfbeis et al. Aug 1994 A
5342789 Chick et al. Aug 1994 A
5356786 Heller et al. Oct 1994 A
5360404 Novacek et al. Nov 1994 A
5372427 Padovani et al. Dec 1994 A
5379238 Stark Jan 1995 A
5384547 Lynk et al. Jan 1995 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5408999 Singh et al. Apr 1995 A
5410326 Goldstein Apr 1995 A
5411647 Johnson et al. May 1995 A
5425868 Pedersen Jun 1995 A
5429602 Hauser Jul 1995 A
5431160 Wilkins Jul 1995 A
5431921 Thombre Jul 1995 A
5438983 Falcone Aug 1995 A
5462645 Albery et al. Oct 1995 A
5472317 Field et al. Dec 1995 A
5489414 Schreiber et al. Feb 1996 A
5497772 Schulman et al. Mar 1996 A
5505828 Wong et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5514718 Lewis et al. May 1996 A
5531878 Vadgama et al. Jul 1996 A
5532686 Urbas et al. Jul 1996 A
5552997 Massart Sep 1996 A
5555190 Derby et al. Sep 1996 A
5564434 Halperin et al. Oct 1996 A
5568400 Stark et al. Oct 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569186 Lord et al. Oct 1996 A
5582184 Erickson et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5593852 Heller et al. Jan 1997 A
5601435 Quy Feb 1997 A
5609575 Larson et al. Mar 1997 A
5628310 Rao et al. May 1997 A
5628324 Sarbach May 1997 A
5634468 Platt et al. Jun 1997 A
5640954 Pfeiffer et al. Jun 1997 A
5653239 Pompei et al. Aug 1997 A
5660163 Schulman et al. Aug 1997 A
5665222 Heller et al. Sep 1997 A
5707502 McCaffrey et al. Jan 1998 A
5711001 Bussan et al. Jan 1998 A
5711861 Ward et al. Jan 1998 A
5724030 Urbas et al. Mar 1998 A
5726646 Bane et al. Mar 1998 A
5733259 Valcke et al. Mar 1998 A
5735285 Albert et al. Apr 1998 A
5748103 Flach et al. May 1998 A
5749907 Mann May 1998 A
5772586 Heinonen et al. Jun 1998 A
5791344 Schulman et al. Aug 1998 A
5804047 Karube et al. Sep 1998 A
5833603 Kovacs et al. Nov 1998 A
5842189 Keeler et al. Nov 1998 A
5891049 Cyrus et al. Apr 1999 A
5899855 Brown May 1999 A
5914026 Blubaugh, Jr. et al. Jun 1999 A
5919141 Money et al. Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5935224 Svancarek et al. Aug 1999 A
5942979 Luppino Aug 1999 A
5951485 Cyrus et al. Sep 1999 A
5957854 Besson et al. Sep 1999 A
5961451 Reber et al. Oct 1999 A
5964993 Blubaugh, Jr. et al. Oct 1999 A
5965380 Heller et al. Oct 1999 A
5971922 Arita et al. Oct 1999 A
5973613 Reis et al. Oct 1999 A
5980708 Champagne et al. Nov 1999 A
5995860 Sun et al. Nov 1999 A
6001067 Shults et al. Dec 1999 A
6024699 Surwit et al. Feb 2000 A
6028413 Brockmann Feb 2000 A
6049727 Crothall Apr 2000 A
6052565 Ishikura et al. Apr 2000 A
6066243 Anderson et al. May 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6091976 Pfeiffer et al. Jul 2000 A
6091987 Thompson Jul 2000 A
6093172 Funderburk et al. Jul 2000 A
6096364 Bok et al. Aug 2000 A
6103033 Say et al. Aug 2000 A
6117290 Say et al. Sep 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6121611 Lindsay et al. Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6130623 MacLellan et al. Oct 2000 A
6134461 Say et al. Oct 2000 A
6143164 Heller et al. Nov 2000 A
6144871 Saito et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6159147 Lichter et al. Dec 2000 A
6162611 Heller et al. Dec 2000 A
6175752 Say et al. Jan 2001 B1
6200265 Walsh et al. Mar 2001 B1
6212416 Ward et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6223283 Chaiken et al. Apr 2001 B1
6233471 Berner et al. May 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6254586 Mann et al. Jul 2001 B1
6270455 Brown Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6283761 Joao Sep 2001 B1
6284478 Heller et al. Sep 2001 B1
6291200 LeJeune et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6294997 Paratore et al. Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6299347 Pompei Oct 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309884 Cooper et al. Oct 2001 B1
6314317 Willis Nov 2001 B1
6329161 Heller et al. Dec 2001 B1
6348640 Navot et al. Feb 2002 B1
6359270 Bridson Mar 2002 B1
6359444 Grimes Mar 2002 B1
6360888 McIvor et al. Mar 2002 B1
6366794 Moussy et al. Apr 2002 B1
6377828 Chaiken et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6387048 Schulman et al. May 2002 B1
6400974 Lesho Jun 2002 B1
6405066 Essenpreis et al. Jun 2002 B1
6413393 Van Antwerp et al. Jul 2002 B1
6416471 Kumar et al. Jul 2002 B1
6418346 Nelson et al. Jul 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6427088 Bowman, IV et al. Jul 2002 B1
6440068 Brown et al. Aug 2002 B1
6471689 Joseph et al. Oct 2002 B1
6478736 Mault Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6493069 Nagashimada et al. Dec 2002 B1
6496729 Thompson Dec 2002 B2
6497655 Linberg et al. Dec 2002 B1
6498043 Schulman et al. Dec 2002 B1
6510344 Halpern Jan 2003 B1
6514718 Heller et al. Feb 2003 B2
6520326 McIvor et al. Feb 2003 B2
6544212 Galley et al. Apr 2003 B2
6546268 Ishikawa et al. Apr 2003 B1
6549796 Sohrab Apr 2003 B2
6551494 Heller et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558321 Burd et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6561975 Pool et al. May 2003 B1
6561978 Conn et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6564105 Starkweather et al. May 2003 B2
6565509 Say et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6572545 Knobbe et al. Jun 2003 B2
6574490 Abbink et al. Jun 2003 B2
6574510 Von Arx et al. Jun 2003 B2
6576101 Heller et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6579231 Phipps Jun 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6585644 Lebel et al. Jul 2003 B2
6591125 Buse et al. Jul 2003 B1
6595919 Berner et al. Jul 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607509 Bobroff et al. Aug 2003 B2
6610012 Mault Aug 2003 B2
6631281 Kastle Oct 2003 B1
6633772 Ford et al. Oct 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6635167 Batman et al. Oct 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6648821 Lebel et al. Nov 2003 B2
6654625 Say et al. Nov 2003 B1
6656114 Poulsen et al. Dec 2003 B1
6658396 Tang et al. Dec 2003 B1
6659948 Lebel et al. Dec 2003 B2
6668196 Villegas et al. Dec 2003 B1
6675030 Ciurczak et al. Jan 2004 B2
6676816 Mao et al. Jan 2004 B2
6687546 Lebel et al. Feb 2004 B2
6689056 Kilcoyne et al. Feb 2004 B1
6694191 Starkweather et al. Feb 2004 B2
6695860 Ward et al. Feb 2004 B1
6698269 Baber et al. Mar 2004 B2
6702857 Brauker et al. Mar 2004 B2
6721582 Trepagnier et al. Apr 2004 B2
6730025 Platt May 2004 B1
6731976 Penn et al. May 2004 B2
6733446 Lebel et al. May 2004 B2
6735183 O'Toole et al. May 2004 B2
6740075 Lebel et al. May 2004 B2
6740518 Duong et al. May 2004 B1
6741877 Shults et al. May 2004 B1
6746582 Heller et al. Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6770030 Schaupp et al. Aug 2004 B1
6789195 Prihoda et al. Sep 2004 B1
6790178 Mault et al. Sep 2004 B1
6804558 Haller et al. Oct 2004 B2
6809653 Mann et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6811533 Lebel et al. Nov 2004 B2
6811534 Bowman, IV et al. Nov 2004 B2
6813519 Lebel et al. Nov 2004 B2
6850790 Berner et al. Feb 2005 B2
6862465 Shults et al. Mar 2005 B2
6865407 Kimball et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6878112 Linberg et al. Apr 2005 B2
6881551 Heller et al. Apr 2005 B2
6882940 Potts et al. Apr 2005 B2
6892085 McIvor et al. May 2005 B2
6895263 Shin et al. May 2005 B2
6895265 Silver May 2005 B2
6923763 Kovatchev et al. Aug 2005 B1
6923764 Aceti et al. Aug 2005 B2
6931327 Goode, Jr. et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6936006 Sabra Aug 2005 B2
6940403 Kail, IV Sep 2005 B2
6941163 Ford et al. Sep 2005 B2
6942518 Liamos et al. Sep 2005 B2
6950708 Bowman, IV et al. Sep 2005 B2
6954662 Freger et al. Oct 2005 B2
6958705 Lebel et al. Oct 2005 B2
6968294 Gutta et al. Nov 2005 B2
6971274 Olin Dec 2005 B2
6974437 Lebel et al. Dec 2005 B2
6983176 Gardner et al. Jan 2006 B2
6990366 Say et al. Jan 2006 B2
6997907 Safabash et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
6999854 Roth Feb 2006 B2
7003336 Holker et al. Feb 2006 B2
7003340 Say et al. Feb 2006 B2
7003341 Say et al. Feb 2006 B2
7009511 Mazar et al. Mar 2006 B2
7011630 Desai et al. Mar 2006 B2
7015817 Copley et al. Mar 2006 B2
7016713 Gardner et al. Mar 2006 B2
7020508 Stivoric et al. Mar 2006 B2
7022072 Fox et al. Apr 2006 B2
7022219 Mansouri et al. Apr 2006 B2
7024236 Ford et al. Apr 2006 B2
7024245 Lebel et al. Apr 2006 B2
7025425 Kovatchev et al. Apr 2006 B2
7027848 Robinson et al. Apr 2006 B2
7027931 Jones et al. Apr 2006 B1
7029444 Shin et al. Apr 2006 B2
7041068 Freeman et al. May 2006 B2
7041468 Drucker et al. May 2006 B2
7043305 KenKnight et al. May 2006 B2
7046153 Oja et al. May 2006 B2
7052472 Miller et al. May 2006 B1
7052483 Wojcik May 2006 B2
7056302 Douglas Jun 2006 B2
7058453 Nelson et al. Jun 2006 B2
7060031 Webb et al. Jun 2006 B2
7074307 Simpson et al. Jul 2006 B2
7081195 Simpson et al. Jul 2006 B2
7082334 Boute et al. Jul 2006 B2
7092891 Maus et al. Aug 2006 B2
7098803 Mann et al. Aug 2006 B2
7108778 Simpson et al. Sep 2006 B2
7110803 Shults et al. Sep 2006 B2
7113821 Sun et al. Sep 2006 B1
7118667 Lee Oct 2006 B2
7123950 Mannheimer Oct 2006 B2
7125382 Zhou et al. Oct 2006 B2
7134999 Brauker et al. Nov 2006 B2
7136689 Shults et al. Nov 2006 B2
7153265 Vachon Dec 2006 B2
7155290 Von Arx et al. Dec 2006 B2
7155729 Andrew et al. Dec 2006 B1
7167818 Brown Jan 2007 B2
7171274 Starkweather et al. Jan 2007 B2
7174199 Berner et al. Feb 2007 B2
7179226 Crothall et al. Feb 2007 B2
7183102 Monfre et al. Feb 2007 B2
7190988 Say et al. Mar 2007 B2
7192450 Brauker et al. Mar 2007 B2
7198606 Boecker et al. Apr 2007 B2
7203549 Schommer et al. Apr 2007 B2
7207974 Safabash et al. Apr 2007 B2
7225535 Feldman et al. Jun 2007 B2
7226442 Sheppard et al. Jun 2007 B2
7226978 Tapsak et al. Jun 2007 B2
7228182 Healy et al. Jun 2007 B2
7237712 DeRocco et al. Jul 2007 B2
7258673 Racchini et al. Aug 2007 B2
7267665 Steil et al. Sep 2007 B2
7276029 Goode, Jr. et al. Oct 2007 B2
7278983 Ireland et al. Oct 2007 B2
7286894 Grant et al. Oct 2007 B1
7295867 Berner et al. Nov 2007 B2
7299082 Feldman et al. Nov 2007 B2
7301463 Paterno Nov 2007 B1
7310544 Brister et al. Dec 2007 B2
7317938 Lorenz et al. Jan 2008 B2
7318816 Bobroff et al. Jan 2008 B2
7324850 Persen et al. Jan 2008 B2
7335294 Heller et al. Feb 2008 B2
7344500 Talbot et al. Mar 2008 B2
7347819 Lebel et al. Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7364592 Carr-Brendel et al. Apr 2008 B2
7366556 Brister et al. Apr 2008 B2
7379765 Petisce et al. May 2008 B2
7384397 Zhang et al. Jun 2008 B2
7387010 Sunshine et al. Jun 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7404796 Ginsberg Jul 2008 B2
7419573 Gundel Sep 2008 B2
7424318 Brister et al. Sep 2008 B2
7460898 Brister et al. Dec 2008 B2
7467003 Brister et al. Dec 2008 B2
7468125 Kraft et al. Dec 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7474992 Ariyur Jan 2009 B2
7492254 Bandy et al. Feb 2009 B2
7494465 Brister et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7519408 Rasdal et al. Apr 2009 B2
7519478 Bartkowiak et al. Apr 2009 B2
7523004 Bartkowiak et al. Apr 2009 B2
7547281 Hayes et al. Jun 2009 B2
7565197 Haubrich et al. Jul 2009 B2
7569030 Lebel et al. Aug 2009 B2
7574266 Dudding et al. Aug 2009 B2
7577469 Aronowitz et al. Aug 2009 B1
7583990 Goode, Jr. et al. Sep 2009 B2
7591801 Brauker et al. Sep 2009 B2
7599726 Goode, Jr. et al. Oct 2009 B2
7602310 Mann et al. Oct 2009 B2
7604178 Stewart Oct 2009 B2
7613491 Boock et al. Nov 2009 B2
7615007 Shults et al. Nov 2009 B2
7618369 Hayter et al. Nov 2009 B2
7620438 He Nov 2009 B2
7630748 Budiman Dec 2009 B2
7632228 Brauker et al. Dec 2009 B2
7635594 Holmes et al. Dec 2009 B2
7637868 Saint et al. Dec 2009 B2
7640048 Dobbles et al. Dec 2009 B2
7651596 Petisce et al. Jan 2010 B2
7651845 Doyle, III et al. Jan 2010 B2
7653425 Hayter et al. Jan 2010 B2
7654956 Brister et al. Feb 2010 B2
7657297 Simpson et al. Feb 2010 B2
7659823 Killian et al. Feb 2010 B1
7668596 Von Arx et al. Feb 2010 B2
7699775 Desai et al. Apr 2010 B2
7699964 Feldman et al. Apr 2010 B2
7711402 Shults et al. May 2010 B2
7711493 Bartkowiak et al. May 2010 B2
7713574 Brister et al. May 2010 B2
7715893 Kamath et al. May 2010 B2
7736310 Taub et al. Jun 2010 B2
7741734 Joannopoulos et al. Jun 2010 B2
7751864 Buck, Jr. Jul 2010 B2
7766829 Sloan et al. Aug 2010 B2
7768386 Hayter et al. Aug 2010 B2
7768387 Fennell et al. Aug 2010 B2
7771352 Shults et al. Aug 2010 B2
7774145 Brauker et al. Aug 2010 B2
7775444 DeRocco et al. Aug 2010 B2
7778680 Goode et al. Aug 2010 B2
7779332 Karr et al. Aug 2010 B2
7782192 Jeckelmann et al. Aug 2010 B2
7783333 Brister et al. Aug 2010 B2
7783442 Mueller, Jr. et al. Aug 2010 B2
7791467 Mazar et al. Sep 2010 B2
7792562 Shults et al. Sep 2010 B2
7811231 Jin et al. Oct 2010 B2
7813809 Strother et al. Oct 2010 B2
7826382 Sicurello et al. Nov 2010 B2
7826981 Goode, Jr. et al. Nov 2010 B2
7831310 Lebel et al. Nov 2010 B2
7842174 Zhou et al. Nov 2010 B2
7857760 Brister et al. Dec 2010 B2
7860574 Von Arx et al. Dec 2010 B2
7874985 Kovatchev et al. Jan 2011 B2
7882611 Shah et al. Feb 2011 B2
7885697 Brister et al. Feb 2011 B2
7889069 Fifolt et al. Feb 2011 B2
7899511 Shults et al. Mar 2011 B2
7899545 John Mar 2011 B2
7905833 Brister et al. Mar 2011 B2
7912674 Killoren Clark et al. Mar 2011 B2
7914450 Goode, Jr. et al. Mar 2011 B2
7916013 Stevenson Mar 2011 B2
7920906 Goode et al. Apr 2011 B2
7928850 Hayter et al. Apr 2011 B2
7938797 Estes May 2011 B2
7941200 Weinert et al. May 2011 B2
7946984 Brister et al. May 2011 B2
7946985 Mastrototaro et al. May 2011 B2
7955258 Goscha et al. Jun 2011 B2
7970448 Shults et al. Jun 2011 B2
7972296 Braig et al. Jul 2011 B2
7974672 Shults et al. Jul 2011 B2
7976466 Ward et al. Jul 2011 B2
7978063 Baldus et al. Jul 2011 B2
7996158 Hayter et al. Aug 2011 B2
7999674 Kamen Aug 2011 B2
8005524 Brauker et al. Aug 2011 B2
8010174 Goode et al. Aug 2011 B2
8010256 Oowada Aug 2011 B2
8060173 Goode, Jr. et al. Nov 2011 B2
8072310 Everhart Dec 2011 B1
8090445 Ginggen Jan 2012 B2
8093991 Stevenson et al. Jan 2012 B2
8094009 Allen et al. Jan 2012 B2
8098159 Batra et al. Jan 2012 B2
8098160 Howarth et al. Jan 2012 B2
8098161 Lavedas Jan 2012 B2
8098201 Choi et al. Jan 2012 B2
8098208 Ficker et al. Jan 2012 B2
8102021 Degani Jan 2012 B2
8102154 Bishop et al. Jan 2012 B2
8102263 Yeo et al. Jan 2012 B2
8102789 Rosar et al. Jan 2012 B2
8103241 Young et al. Jan 2012 B2
8103325 Swedlow et al. Jan 2012 B2
8103471 Hayter Jan 2012 B2
8111042 Bennett Feb 2012 B2
8115488 McDowell Feb 2012 B2
8116681 Baarman Feb 2012 B2
8116683 Baarman Feb 2012 B2
8117481 Anselmi et al. Feb 2012 B2
8120493 Burr Feb 2012 B2
8124452 Sheats Feb 2012 B2
8130093 Mazar et al. Mar 2012 B2
8131351 Kalgren et al. Mar 2012 B2
8131365 Zhang et al. Mar 2012 B2
8131565 Dicks et al. Mar 2012 B2
8132037 Fehr et al. Mar 2012 B2
8135352 Langsweirdt et al. Mar 2012 B2
8136735 Arai et al. Mar 2012 B2
8138925 Downie et al. Mar 2012 B2
8140160 Pless et al. Mar 2012 B2
8140168 Olson et al. Mar 2012 B2
8140299 Siess Mar 2012 B2
8140312 Hayter et al. Mar 2012 B2
8150321 Winter et al. Apr 2012 B2
8150516 Levine et al. Apr 2012 B2
8160669 Brauker et al. Apr 2012 B2
8160900 Taub et al. Apr 2012 B2
8170803 Kamath et al. May 2012 B2
8179266 Hermle May 2012 B2
8192394 Estes et al. Jun 2012 B2
8216138 McGarraugh Jul 2012 B1
8216139 Brauker et al. Jul 2012 B2
8239166 Hayter et al. Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8260558 Hayter et al. Sep 2012 B2
8282549 Brauker et al. Oct 2012 B2
8306766 Mueller, Jr. et al. Nov 2012 B2
8374667 Brauker et al. Feb 2013 B2
8374668 Hayter et al. Feb 2013 B1
8376945 Hayter et al. Feb 2013 B2
8377271 Mao et al. Feb 2013 B2
8409093 Bugler Apr 2013 B2
8444560 Hayter et al. May 2013 B2
8461985 Fennell et al. Jun 2013 B2
8478557 Hayter et al. Jul 2013 B2
8484005 Hayter et al. Jul 2013 B2
8543354 Luo et al. Sep 2013 B2
8560038 Hayter et al. Oct 2013 B2
8571808 Hayter Oct 2013 B2
8583205 Budiman et al. Nov 2013 B2
8597570 Terashima et al. Dec 2013 B2
8600681 Hayter et al. Dec 2013 B2
8608923 Zhou et al. Dec 2013 B2
8612163 Hayter et al. Dec 2013 B2
8657746 Roy Feb 2014 B2
8682615 Hayter et al. Mar 2014 B2
8710993 Hayter et al. Apr 2014 B2
8834366 Hayter et al. Sep 2014 B2
8845536 Brauker et al. Sep 2014 B2
9000914 Baker et al. Apr 2015 B2
9060719 Hayter et al. Jun 2015 B2
9119528 Cobelli et al. Sep 2015 B2
9125548 Hayter Sep 2015 B2
9289179 Hayter et al. Mar 2016 B2
9398872 Hayter et al. Jul 2016 B2
9408566 Hayter et al. Aug 2016 B2
9439586 Bugler Sep 2016 B2
9483608 Hayter et al. Nov 2016 B2
9558325 Hayter et al. Jan 2017 B2
9743872 Hayter et al. Aug 2017 B2
9797880 Hayter et al. Oct 2017 B2
9801541 Mensinger et al. Oct 2017 B2
9804148 Hayter et al. Oct 2017 B2
9833181 Hayter et al. Dec 2017 B2
9980140 Spencer et al. May 2018 B1
10136847 Hayter et al. Nov 2018 B2
10375222 Mandapaka et al. Aug 2019 B2
10702215 Hampapuram et al. Jul 2020 B2
10855788 Arabo et al. Dec 2020 B2
10939859 Hayter Mar 2021 B2
11213204 Mensinger et al. Jan 2022 B2
11991175 Rolfe et al. May 2024 B2
20010037366 Webb et al. Nov 2001 A1
20020016534 Trepagnier et al. Feb 2002 A1
20020019022 Dunn et al. Feb 2002 A1
20020032531 Mansky et al. Mar 2002 A1
20020042090 Heller et al. Apr 2002 A1
20020054320 Ogino May 2002 A1
20020057993 Maisey et al. May 2002 A1
20020065454 Lebel et al. May 2002 A1
20020068860 Clark Jun 2002 A1
20020095076 Krausman et al. Jul 2002 A1
20020103499 Perez et al. Aug 2002 A1
20020106709 Potts et al. Aug 2002 A1
20020117639 Paolini et al. Aug 2002 A1
20020120186 Keimel Aug 2002 A1
20020128594 Das et al. Sep 2002 A1
20020147135 Schnell Oct 2002 A1
20020150959 Lejeune et al. Oct 2002 A1
20020156355 Gough Oct 2002 A1
20020161288 Shin et al. Oct 2002 A1
20020169635 Shillingburg Nov 2002 A1
20030004403 Drinan et al. Jan 2003 A1
20030023317 Brauker et al. Jan 2003 A1
20030023461 Quintanilla et al. Jan 2003 A1
20030028089 Galley et al. Feb 2003 A1
20030032077 Itoh et al. Feb 2003 A1
20030032867 Crothall et al. Feb 2003 A1
20030032874 Rhodes et al. Feb 2003 A1
20030042137 Mao et al. Mar 2003 A1
20030050546 Desai et al. Mar 2003 A1
20030054428 Monfre et al. Mar 2003 A1
20030060692 Ruchti et al. Mar 2003 A1
20030060753 Starkweather et al. Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030100040 Bonnecaze et al. May 2003 A1
20030100821 Heller et al. May 2003 A1
20030114897 Von Arx et al. Jun 2003 A1
20030125612 Fox et al. Jul 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030134347 Heller et al. Jul 2003 A1
20030147515 Kai et al. Aug 2003 A1
20030168338 Gao et al. Sep 2003 A1
20030176933 Lebel et al. Sep 2003 A1
20030187338 Say et al. Oct 2003 A1
20030191377 Robinson et al. Oct 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030199790 Boecker et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030211617 Jones Nov 2003 A1
20030212317 Kovatchev et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030216630 Jersey-Willuhn et al. Nov 2003 A1
20030217966 Tapsak et al. Nov 2003 A1
20030235817 Bartkowiak et al. Dec 2003 A1
20040010186 Kimball et al. Jan 2004 A1
20040010207 Flaherty et al. Jan 2004 A1
20040011671 Shults et al. Jan 2004 A1
20040024553 Monfre et al. Feb 2004 A1
20040034289 Teller et al. Feb 2004 A1
20040039298 Abreu Feb 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040041749 Dixon Mar 2004 A1
20040045879 Shults et al. Mar 2004 A1
20040054263 Moerman et al. Mar 2004 A1
20040063435 Sakamoto et al. Apr 2004 A1
20040064068 DeNuzzio et al. Apr 2004 A1
20040099529 Mao et al. May 2004 A1
20040106858 Say et al. Jun 2004 A1
20040111017 Say et al. Jun 2004 A1
20040117204 Mazar et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040133164 Funderburk et al. Jul 2004 A1
20040133390 Osorio et al. Jul 2004 A1
20040135571 Uutela et al. Jul 2004 A1
20040135684 Steinthal et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040142403 Hetzel et al. Jul 2004 A1
20040146909 Duong et al. Jul 2004 A1
20040147872 Thompson Jul 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040162678 Hetzel et al. Aug 2004 A1
20040167464 Ireland et al. Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040171921 Say et al. Sep 2004 A1
20040176672 Silver et al. Sep 2004 A1
20040186362 Brauker et al. Sep 2004 A1
20040186365 Jin et al. Sep 2004 A1
20040193020 Chiba et al. Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040197846 Hockersmith et al. Oct 2004 A1
20040199056 Husemann et al. Oct 2004 A1
20040199059 Brauker et al. Oct 2004 A1
20040204687 Mogensen et al. Oct 2004 A1
20040204868 Maynard et al. Oct 2004 A1
20040219664 Heller et al. Nov 2004 A1
20040225338 Lebel et al. Nov 2004 A1
20040236200 Say et al. Nov 2004 A1
20040249253 Racchini et al. Dec 2004 A1
20040254433 Bandis et al. Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20040260478 Schwamm Dec 2004 A1
20040267300 Mace Dec 2004 A1
20050001024 Kusaka et al. Jan 2005 A1
20050004439 Shin et al. Jan 2005 A1
20050004494 Perez et al. Jan 2005 A1
20050010269 Lebel et al. Jan 2005 A1
20050017864 Tsoukalis Jan 2005 A1
20050027177 Shin et al. Feb 2005 A1
20050027180 Goode et al. Feb 2005 A1
20050027181 Goode et al. Feb 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050027462 Goode et al. Feb 2005 A1
20050027463 Goode et al. Feb 2005 A1
20050031689 Shults et al. Feb 2005 A1
20050038332 Saidara et al. Feb 2005 A1
20050043598 Goode, Jr. et al. Feb 2005 A1
20050049179 Davidson et al. Mar 2005 A1
20050049473 Desai et al. Mar 2005 A1
20050070774 Addison et al. Mar 2005 A1
20050070777 Cho et al. Mar 2005 A1
20050090607 Tapsak et al. Apr 2005 A1
20050096511 Fox et al. May 2005 A1
20050096512 Fox et al. May 2005 A1
20050096516 Soykan et al. May 2005 A1
20050112169 Brauker et al. May 2005 A1
20050113648 Yang et al. May 2005 A1
20050113653 Fox et al. May 2005 A1
20050113886 Fischell et al. May 2005 A1
20050114068 Chey et al. May 2005 A1
20050115832 Simpson et al. Jun 2005 A1
20050116683 Cheng et al. Jun 2005 A1
20050121322 Say et al. Jun 2005 A1
20050131346 Douglas Jun 2005 A1
20050134731 Lee et al. Jun 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143635 Kamath et al. Jun 2005 A1
20050148890 Hastings Jul 2005 A1
20050154271 Rasdal et al. Jul 2005 A1
20050176136 Burd et al. Aug 2005 A1
20050177398 Watanabe et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050187442 Cho et al. Aug 2005 A1
20050187720 Goode, Jr. et al. Aug 2005 A1
20050192494 Ginsberg Sep 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050195930 Spital et al. Sep 2005 A1
20050196821 Monfre et al. Sep 2005 A1
20050197793 Baker, Jr. Sep 2005 A1
20050199494 Say et al. Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050204134 Von Arx et al. Sep 2005 A1
20050209515 Hockersmith et al. Sep 2005 A1
20050214892 Kovatchev et al. Sep 2005 A1
20050236361 Ufer et al. Oct 2005 A1
20050239154 Feldman et al. Oct 2005 A1
20050239156 Drucker et al. Oct 2005 A1
20050241957 Mao et al. Nov 2005 A1
20050245795 Goode, Jr. et al. Nov 2005 A1
20050245799 Brauker et al. Nov 2005 A1
20050245839 Stivoric et al. Nov 2005 A1
20050245904 Estes et al. Nov 2005 A1
20050251033 Scarantino et al. Nov 2005 A1
20050272985 Kotulla et al. Dec 2005 A1
20050277164 Drucker et al. Dec 2005 A1
20050277912 John Dec 2005 A1
20050280521 Mizumaki Dec 2005 A1
20050287620 Heller et al. Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060001551 Kraft et al. Jan 2006 A1
20060004270 Bedard et al. Jan 2006 A1
20060010098 Goodnow et al. Jan 2006 A1
20060011474 Schulein et al. Jan 2006 A1
20060015020 Neale et al. Jan 2006 A1
20060015024 Brister et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060017923 Ruchti et al. Jan 2006 A1
20060019327 Brister et al. Jan 2006 A1
20060020186 Brister et al. Jan 2006 A1
20060020187 Brister et al. Jan 2006 A1
20060020188 Kamath et al. Jan 2006 A1
20060020189 Brister et al. Jan 2006 A1
20060020190 Kamath et al. Jan 2006 A1
20060020191 Brister et al. Jan 2006 A1
20060020192 Brister et al. Jan 2006 A1
20060020300 Nghiem et al. Jan 2006 A1
20060025663 Talbot et al. Feb 2006 A1
20060029177 Cranford, Jr. et al. Feb 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060036139 Brister et al. Feb 2006 A1
20060036140 Brister et al. Feb 2006 A1
20060036141 Kamath et al. Feb 2006 A1
20060036142 Brister et al. Feb 2006 A1
20060036143 Brister et al. Feb 2006 A1
20060036144 Brister et al. Feb 2006 A1
20060036145 Brister et al. Feb 2006 A1
20060058588 Zdeblick Mar 2006 A1
20060079740 Silver et al. Apr 2006 A1
20060091006 Wang et al. May 2006 A1
20060094947 Kovatchev et al. May 2006 A1
20060142651 Brister et al. Jun 2006 A1
20060154642 Scannell Jul 2006 A1
20060155180 Brister et al. Jul 2006 A1
20060156796 Burke et al. Jul 2006 A1
20060166629 Reggiardo Jul 2006 A1
20060173260 Gaoni et al. Aug 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060183984 Dobbles et al. Aug 2006 A1
20060183985 Brister et al. Aug 2006 A1
20060189851 Tivig et al. Aug 2006 A1
20060189863 Peyser et al. Aug 2006 A1
20060193375 Lee Aug 2006 A1
20060202805 Schulman et al. Sep 2006 A1
20060211072 Ryan et al. Sep 2006 A1
20060222566 Brauker et al. Oct 2006 A1
20060224109 Steil et al. Oct 2006 A1
20060224141 Rush et al. Oct 2006 A1
20060229512 Petisce et al. Oct 2006 A1
20060247508 Fennell Nov 2006 A1
20060247710 Goetz et al. Nov 2006 A1
20060247985 Liamos et al. Nov 2006 A1
20060253296 Liisberg et al. Nov 2006 A1
20060258929 Goode et al. Nov 2006 A1
20060272652 Stocker et al. Dec 2006 A1
20060276771 Galley et al. Dec 2006 A1
20060281985 Ward et al. Dec 2006 A1
20060287691 Drew Dec 2006 A1
20060290496 Peeters et al. Dec 2006 A1
20060293607 Alt et al. Dec 2006 A1
20070007133 Mang et al. Jan 2007 A1
20070010950 Abensour et al. Jan 2007 A1
20070016381 Kamath et al. Jan 2007 A1
20070017983 Frank et al. Jan 2007 A1
20070027381 Stafford Feb 2007 A1
20070027507 Burdett et al. Feb 2007 A1
20070032706 Kamath et al. Feb 2007 A1
20070032717 Brister et al. Feb 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070038044 Dobbles et al. Feb 2007 A1
20070055799 Koehler et al. Mar 2007 A1
20070060803 Liljeryd et al. Mar 2007 A1
20070060814 Stafford Mar 2007 A1
20070060869 Tolle et al. Mar 2007 A1
20070060979 Strother et al. Mar 2007 A1
20070066873 Kamath et al. Mar 2007 A1
20070066956 Finkel Mar 2007 A1
20070071681 Gadkar et al. Mar 2007 A1
20070073129 Shah et al. Mar 2007 A1
20070078320 Stafford Apr 2007 A1
20070078321 Mazza et al. Apr 2007 A1
20070078322 Stafford Apr 2007 A1
20070078323 Reggiardo et al. Apr 2007 A1
20070078818 Zivitz et al. Apr 2007 A1
20070093786 Goldsmith et al. Apr 2007 A1
20070094216 Mathias et al. Apr 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070106135 Sloan et al. May 2007 A1
20070107973 Jiang et al. May 2007 A1
20070118030 Bruce et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070124002 Estes et al. May 2007 A1
20070129621 Kellogg et al. Jun 2007 A1
20070149875 Ouyang et al. Jun 2007 A1
20070151869 Heller et al. Jul 2007 A1
20070153705 Rosar et al. Jul 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070156094 Safabash et al. Jul 2007 A1
20070163880 Woo et al. Jul 2007 A1
20070168224 Letzt et al. Jul 2007 A1
20070173706 Neinast et al. Jul 2007 A1
20070173709 Petisce et al. Jul 2007 A1
20070173710 Petisce et al. Jul 2007 A1
20070173761 Kanderian et al. Jul 2007 A1
20070179349 Hoyme et al. Aug 2007 A1
20070179352 Randlov et al. Aug 2007 A1
20070191701 Feldman et al. Aug 2007 A1
20070191702 Yodfat et al. Aug 2007 A1
20070202562 Curry Aug 2007 A1
20070203407 Hoss et al. Aug 2007 A1
20070203966 Brauker et al. Aug 2007 A1
20070208244 Brauker et al. Sep 2007 A1
20070208246 Brauker et al. Sep 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070228071 Kamen et al. Oct 2007 A1
20070232878 Kovatchev et al. Oct 2007 A1
20070232880 Siddiqui et al. Oct 2007 A1
20070235331 Simpson et al. Oct 2007 A1
20070244383 Talbot et al. Oct 2007 A1
20070249922 Peyser et al. Oct 2007 A1
20070253021 Mehta et al. Nov 2007 A1
20070255116 Mehta et al. Nov 2007 A1
20070255321 Gerber et al. Nov 2007 A1
20070255348 Holtzclaw Nov 2007 A1
20070255531 Drew Nov 2007 A1
20070258395 Jollota et al. Nov 2007 A1
20070270672 Hayter Nov 2007 A1
20070271285 Eichorn et al. Nov 2007 A1
20070282299 Hellwig Dec 2007 A1
20070285238 Batra Dec 2007 A1
20070299617 Willis Dec 2007 A1
20080004515 Jennewine et al. Jan 2008 A1
20080004601 Jennewine et al. Jan 2008 A1
20080009692 Stafford Jan 2008 A1
20080012701 Kass et al. Jan 2008 A1
20080017522 Heller et al. Jan 2008 A1
20080018433 Pitt-Pladdy Jan 2008 A1
20080021436 Wolpert et al. Jan 2008 A1
20080021666 Goode, Jr. et al. Jan 2008 A1
20080021972 Huelskamp et al. Jan 2008 A1
20080029391 Mao et al. Feb 2008 A1
20080030369 Mann et al. Feb 2008 A1
20080033254 Kamath et al. Feb 2008 A1
20080039702 Hayter et al. Feb 2008 A1
20080045824 Tapsak et al. Feb 2008 A1
20080057484 Miyata et al. Mar 2008 A1
20080058625 McGarraugh et al. Mar 2008 A1
20080058626 Miyata et al. Mar 2008 A1
20080058678 Miyata et al. Mar 2008 A1
20080058773 John Mar 2008 A1
20080060955 Goodnow Mar 2008 A1
20080061961 John Mar 2008 A1
20080064937 McGarraugh et al. Mar 2008 A1
20080064943 Talbot et al. Mar 2008 A1
20080071156 Brister et al. Mar 2008 A1
20080071157 McGarraugh et al. Mar 2008 A1
20080071158 McGarraugh et al. Mar 2008 A1
20080071328 Haubrich et al. Mar 2008 A1
20080077073 Keenan et al. Mar 2008 A1
20080081958 Denison Apr 2008 A1
20080081977 Hayter et al. Apr 2008 A1
20080083617 Simpson et al. Apr 2008 A1
20080086042 Brister et al. Apr 2008 A1
20080086044 Brister et al. Apr 2008 A1
20080086273 Shults et al. Apr 2008 A1
20080087544 Zhou et al. Apr 2008 A1
20080092638 Brenneman et al. Apr 2008 A1
20080097246 Stafford Apr 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080103447 Reggiardo et al. May 2008 A1
20080108942 Brister et al. May 2008 A1
20080114228 McCluskey et al. May 2008 A1
20080119705 Patel et al. May 2008 A1
20080119710 Reggiardo et al. May 2008 A1
20080139910 Mastrototaro et al. Jun 2008 A1
20080154099 Aspel et al. Jun 2008 A1
20080154101 Jain Jun 2008 A1
20080154513 Kovatchev et al. Jun 2008 A1
20080161666 Feldman et al. Jul 2008 A1
20080167543 Say et al. Jul 2008 A1
20080167572 Stivoric et al. Jul 2008 A1
20080172205 Breton et al. Jul 2008 A1
20080177149 Weinert et al. Jul 2008 A1
20080177165 Blomquist et al. Jul 2008 A1
20080182537 Manku et al. Jul 2008 A1
20080183060 Steil et al. Jul 2008 A1
20080183061 Goode et al. Jul 2008 A1
20080183399 Goode et al. Jul 2008 A1
20080188731 Brister et al. Aug 2008 A1
20080188796 Steil et al. Aug 2008 A1
20080189051 Goode et al. Aug 2008 A1
20080194934 Ray et al. Aug 2008 A1
20080194935 Brister et al. Aug 2008 A1
20080194936 Goode et al. Aug 2008 A1
20080194937 Goode et al. Aug 2008 A1
20080194938 Brister et al. Aug 2008 A1
20080195232 Carr-Brendel et al. Aug 2008 A1
20080195967 Goode et al. Aug 2008 A1
20080197024 Simpson et al. Aug 2008 A1
20080200788 Brister et al. Aug 2008 A1
20080200789 Brister et al. Aug 2008 A1
20080200791 Simpson et al. Aug 2008 A1
20080201325 Doniger et al. Aug 2008 A1
20080208025 Shults et al. Aug 2008 A1
20080208026 Noujaim et al. Aug 2008 A1
20080208113 Damiano et al. Aug 2008 A1
20080214900 Fennell et al. Sep 2008 A1
20080214910 Buck Sep 2008 A1
20080214915 Brister et al. Sep 2008 A1
20080214918 Brister et al. Sep 2008 A1
20080228051 Shults et al. Sep 2008 A1
20080228054 Shults et al. Sep 2008 A1
20080228055 Sher Sep 2008 A1
20080234663 Yodfat et al. Sep 2008 A1
20080234943 Ray et al. Sep 2008 A1
20080234992 Ray et al. Sep 2008 A1
20080235469 Drew Sep 2008 A1
20080242961 Brister et al. Oct 2008 A1
20080242963 Essenpreis et al. Oct 2008 A1
20080254544 Modzelewski et al. Oct 2008 A1
20080255434 Hayter et al. Oct 2008 A1
20080255437 Hayter Oct 2008 A1
20080255438 Saidara et al. Oct 2008 A1
20080255808 Hayter Oct 2008 A1
20080256048 Hayter Oct 2008 A1
20080262469 Brister et al. Oct 2008 A1
20080269714 Mastrototaro et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080275313 Brister et al. Nov 2008 A1
20080278332 Fennel et al. Nov 2008 A1
20080278333 Fennell et al. Nov 2008 A1
20080287761 Hayter Nov 2008 A1
20080287762 Hayter Nov 2008 A1
20080287763 Hayter Nov 2008 A1
20080287764 Rasdal et al. Nov 2008 A1
20080287765 Rasdal et al. Nov 2008 A1
20080287766 Rasdal et al. Nov 2008 A1
20080288180 Hayter Nov 2008 A1
20080288204 Hayter et al. Nov 2008 A1
20080294024 Cosentino et al. Nov 2008 A1
20080296155 Shults et al. Dec 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080306368 Goode et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306435 Kamath et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20080312518 Jina et al. Dec 2008 A1
20080312841 Hayter Dec 2008 A1
20080312842 Hayter Dec 2008 A1
20080312844 Hayter et al. Dec 2008 A1
20080312845 Hayter et al. Dec 2008 A1
20080314395 Kovatchev et al. Dec 2008 A1
20080319085 Wright et al. Dec 2008 A1
20080319279 Ramsay et al. Dec 2008 A1
20080319295 Bernstein et al. Dec 2008 A1
20080319296 Bernstein et al. Dec 2008 A1
20090005665 Hayter et al. Jan 2009 A1
20090005666 Shin et al. Jan 2009 A1
20090005729 Hendrixson et al. Jan 2009 A1
20090006034 Hayter et al. Jan 2009 A1
20090006061 Thukral et al. Jan 2009 A1
20090006133 Weinert et al. Jan 2009 A1
20090012376 Agus Jan 2009 A1
20090012379 Goode et al. Jan 2009 A1
20090018424 Kamath et al. Jan 2009 A1
20090018425 Ouyang et al. Jan 2009 A1
20090024050 Jung Jan 2009 A1
20090030293 Cooper et al. Jan 2009 A1
20090030294 Petisce et al. Jan 2009 A1
20090030641 Fjield et al. Jan 2009 A1
20090033482 Hayter et al. Feb 2009 A1
20090036747 Hayter et al. Feb 2009 A1
20090036758 Brauker et al. Feb 2009 A1
20090036760 Hayter Feb 2009 A1
20090036763 Brauker et al. Feb 2009 A1
20090040022 Finkenzeller Feb 2009 A1
20090043181 Brauker et al. Feb 2009 A1
20090043182 Brauker et al. Feb 2009 A1
20090043525 Brauker et al. Feb 2009 A1
20090043541 Brauker et al. Feb 2009 A1
20090043542 Brauker et al. Feb 2009 A1
20090045055 Rhodes et al. Feb 2009 A1
20090048503 Dalal et al. Feb 2009 A1
20090054745 Jennewine et al. Feb 2009 A1
20090054747 Fennell Feb 2009 A1
20090054748 Feldman et al. Feb 2009 A1
20090054749 He Feb 2009 A1
20090054753 Robinson et al. Feb 2009 A1
20090055149 Hayter et al. Feb 2009 A1
20090062633 Brauker et al. Mar 2009 A1
20090062635 Brauker et al. Mar 2009 A1
20090062767 VanAntwerp et al. Mar 2009 A1
20090063187 Johnson et al. Mar 2009 A1
20090063402 Hayter Mar 2009 A1
20090076356 Simpson et al. Mar 2009 A1
20090076360 Brister et al. Mar 2009 A1
20090076361 Kamath et al. Mar 2009 A1
20090082693 Stafford Mar 2009 A1
20090085768 Patel et al. Apr 2009 A1
20090085873 Betts et al. Apr 2009 A1
20090088614 Taub Apr 2009 A1
20090093687 Telfort et al. Apr 2009 A1
20090099436 Brister et al. Apr 2009 A1
20090105554 Stahmann et al. Apr 2009 A1
20090105560 Solomon Apr 2009 A1
20090105568 Bugler Apr 2009 A1
20090105570 Sloan et al. Apr 2009 A1
20090105571 Fennell et al. Apr 2009 A1
20090105636 Hayter et al. Apr 2009 A1
20090112478 Mueller, Jr. et al. Apr 2009 A1
20090112626 Talbot et al. Apr 2009 A1
20090124877 Goode et al. May 2009 A1
20090124878 Goode et al. May 2009 A1
20090124879 Brister et al. May 2009 A1
20090124964 Leach et al. May 2009 A1
20090131768 Simpson et al. May 2009 A1
20090131769 Leach et al. May 2009 A1
20090131776 Simpson et al. May 2009 A1
20090131777 Simpson et al. May 2009 A1
20090137886 Shariati et al. May 2009 A1
20090137887 Shariati et al. May 2009 A1
20090143659 Li et al. Jun 2009 A1
20090143660 Brister et al. Jun 2009 A1
20090149717 Brauer et al. Jun 2009 A1
20090149728 Van Antwerp et al. Jun 2009 A1
20090150186 Cohen et al. Jun 2009 A1
20090156919 Brister et al. Jun 2009 A1
20090156924 Shariati et al. Jun 2009 A1
20090163790 Brister et al. Jun 2009 A1
20090163791 Brister et al. Jun 2009 A1
20090163855 Shin et al. Jun 2009 A1
20090164190 Hayter Jun 2009 A1
20090164239 Hayter et al. Jun 2009 A1
20090164251 Hayter Jun 2009 A1
20090177068 Stivoric et al. Jul 2009 A1
20090178459 Li et al. Jul 2009 A1
20090182217 Li et al. Jul 2009 A1
20090189738 Hermle Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192380 Shariati et al. Jul 2009 A1
20090192722 Shariati et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090192751 Kamath et al. Jul 2009 A1
20090198118 Hayter et al. Aug 2009 A1
20090203981 Brauker et al. Aug 2009 A1
20090204341 Brauker et al. Aug 2009 A1
20090216100 Ebner et al. Aug 2009 A1
20090216103 Brister et al. Aug 2009 A1
20090221890 Saffer et al. Sep 2009 A1
20090227855 Hill et al. Sep 2009 A1
20090234200 Husheer Sep 2009 A1
20090240120 Mensinger et al. Sep 2009 A1
20090240128 Mensinger et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090240440 Shurabura et al. Sep 2009 A1
20090242399 Kamath et al. Oct 2009 A1
20090242425 Kamath et al. Oct 2009 A1
20090247855 Boock et al. Oct 2009 A1
20090247856 Boock et al. Oct 2009 A1
20090247857 Harper et al. Oct 2009 A1
20090247931 Damgaard-Sorensen Oct 2009 A1
20090253973 Bashan et al. Oct 2009 A1
20090257911 Thomas et al. Oct 2009 A1
20090259118 Feldman et al. Oct 2009 A1
20090267765 Greene et al. Oct 2009 A1
20090275815 Bickoff et al. Nov 2009 A1
20090287073 Boock et al. Nov 2009 A1
20090287074 Shults et al. Nov 2009 A1
20090289796 Blumberg Nov 2009 A1
20090292188 Hoss et al. Nov 2009 A1
20090296742 Sicurello et al. Dec 2009 A1
20090298182 Schulat et al. Dec 2009 A1
20090299155 Yang et al. Dec 2009 A1
20090299156 Simpson et al. Dec 2009 A1
20090299162 Brauker et al. Dec 2009 A1
20090299276 Brauker et al. Dec 2009 A1
20090312622 Regittnig Dec 2009 A1
20100010324 Brauker et al. Jan 2010 A1
20100010329 Taub et al. Jan 2010 A1
20100010330 Rankers Jan 2010 A1
20100010331 Brauker et al. Jan 2010 A1
20100010332 Brauker et al. Jan 2010 A1
20100014626 Fennell et al. Jan 2010 A1
20100016687 Brauker et al. Jan 2010 A1
20100016698 Rasdal et al. Jan 2010 A1
20100022855 Brauker et al. Jan 2010 A1
20100022988 Wochner et al. Jan 2010 A1
20100030038 Brauker et al. Feb 2010 A1
20100030053 Goode, Jr. et al. Feb 2010 A1
20100030484 Brauker et al. Feb 2010 A1
20100030485 Brauker et al. Feb 2010 A1
20100036215 Goode, Jr. et al. Feb 2010 A1
20100036216 Goode, Jr. et al. Feb 2010 A1
20100036222 Goode, Jr. et al. Feb 2010 A1
20100036223 Goode, Jr. et al. Feb 2010 A1
20100036225 Goode, Jr. et al. Feb 2010 A1
20100041971 Goode, Jr. et al. Feb 2010 A1
20100045425 Chivallier Feb 2010 A1
20100045465 Brauker et al. Feb 2010 A1
20100049024 Saint et al. Feb 2010 A1
20100056992 Hayter et al. Mar 2010 A1
20100057040 Hayter Mar 2010 A1
20100057041 Hayter Mar 2010 A1
20100057042 Hayter Mar 2010 A1
20100057044 Hayter Mar 2010 A1
20100057057 Hayter et al. Mar 2010 A1
20100063373 Kamath et al. Mar 2010 A1
20100064764 Hayter et al. Mar 2010 A1
20100075353 Heaton Mar 2010 A1
20100076283 Simpson et al. Mar 2010 A1
20100081906 Hayter et al. Apr 2010 A1
20100081908 Dobbles et al. Apr 2010 A1
20100081909 Budiman et al. Apr 2010 A1
20100081910 Brister et al. Apr 2010 A1
20100081953 Syeda-Mahmood et al. Apr 2010 A1
20100087724 Brauker et al. Apr 2010 A1
20100094111 Heller et al. Apr 2010 A1
20100094251 Estes et al. Apr 2010 A1
20100096259 Zhang et al. Apr 2010 A1
20100099970 Shults et al. Apr 2010 A1
20100099971 Shults et al. Apr 2010 A1
20100105999 Dixon et al. Apr 2010 A1
20100119693 Tapsak et al. May 2010 A1
20100121167 McGarraugh et al. May 2010 A1
20100121169 Petisce et al. May 2010 A1
20100141656 Krieftewirth Jun 2010 A1
20100152554 Steine et al. Jun 2010 A1
20100152561 Goodnow et al. Jun 2010 A1
20100160759 Celentano et al. Jun 2010 A1
20100168538 Keenan et al. Jul 2010 A1
20100168546 Kamath et al. Jul 2010 A1
20100174266 Estes Jul 2010 A1
20100185175 Kamen et al. Jul 2010 A1
20100190435 Cook et al. Jul 2010 A1
20100191082 Brister et al. Jul 2010 A1
20100191085 Budiman Jul 2010 A1
20100191472 Doniger et al. Jul 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100198314 Wei Aug 2010 A1
20100204557 Kiaie et al. Aug 2010 A1
20100213080 Celentano et al. Aug 2010 A1
20100230285 Hoss et al. Sep 2010 A1
20100234710 Budiman et al. Sep 2010 A1
20100240975 Goode et al. Sep 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100268157 Wehba et al. Oct 2010 A1
20100268477 Mueller, Jr. et al. Oct 2010 A1
20100274111 Say et al. Oct 2010 A1
20100274515 Hoss et al. Oct 2010 A1
20100275108 Sloan et al. Oct 2010 A1
20100292948 Feldman et al. Nov 2010 A1
20100312176 Lauer et al. Dec 2010 A1
20100313105 Nekoomaram et al. Dec 2010 A1
20110004085 Mensinger et al. Jan 2011 A1
20110004276 Blair et al. Jan 2011 A1
20110024043 Boock et al. Feb 2011 A1
20110024307 Simpson et al. Feb 2011 A1
20110027127 Simpson et al. Feb 2011 A1
20110027453 Boock et al. Feb 2011 A1
20110027458 Boock et al. Feb 2011 A1
20110028815 Simpson et al. Feb 2011 A1
20110028816 Simpson et al. Feb 2011 A1
20110031986 Bhat et al. Feb 2011 A1
20110036714 Zhou et al. Feb 2011 A1
20110040163 Telson et al. Feb 2011 A1
20110054282 Nekoomaram et al. Mar 2011 A1
20110054334 Fischell Mar 2011 A1
20110060530 Fennell Mar 2011 A1
20110077490 Simpson et al. Mar 2011 A1
20110077494 Doniger et al. Mar 2011 A1
20110081726 Berman Apr 2011 A1
20110106011 Cinar et al. May 2011 A1
20110112696 Yodfat et al. May 2011 A1
20110131307 El Bazzal et al. Jun 2011 A1
20110148905 Simmons et al. Jun 2011 A1
20110152637 Kateraas et al. Jun 2011 A1
20110173308 Gutekunst Jul 2011 A1
20110178717 Goodnow et al. Jul 2011 A1
20110184267 Duke et al. Jul 2011 A1
20110193704 Harper et al. Aug 2011 A1
20110202495 Gawlick Aug 2011 A1
20110208027 Wagner et al. Aug 2011 A1
20110213225 Bernstein et al. Sep 2011 A1
20110257895 Brauker et al. Oct 2011 A1
20110282327 Kellogg et al. Nov 2011 A1
20110287528 Fern et al. Nov 2011 A1
20110289497 Kiaie et al. Nov 2011 A1
20110320130 Valdes et al. Dec 2011 A1
20110320167 Budiman Dec 2011 A1
20120004512 Kovatchev et al. Jan 2012 A1
20120078071 Bohm et al. Mar 2012 A1
20120088995 Fennell et al. Apr 2012 A1
20120108934 Valdes et al. May 2012 A1
20120165626 Irina et al. Jun 2012 A1
20120165640 Galley et al. Jun 2012 A1
20120173200 Breton et al. Jul 2012 A1
20120185416 Baras et al. Jul 2012 A1
20120186997 Li et al. Jul 2012 A1
20120190989 Kaiser et al. Jul 2012 A1
20120245447 Karan et al. Sep 2012 A1
20120283542 McGarraugh Nov 2012 A1
20120313785 Hanson et al. Dec 2012 A1
20120318670 Karinka et al. Dec 2012 A1
20130035575 Mayou et al. Feb 2013 A1
20130109944 Sparacino et al. May 2013 A1
20130130215 Bock et al. May 2013 A1
20130137953 Harper et al. May 2013 A1
20130184547 Taub et al. Jul 2013 A1
20130225959 Bugler Aug 2013 A1
20130231541 Hayter et al. Sep 2013 A1
20130235166 Jones et al. Sep 2013 A1
20130245547 El-Khatib et al. Sep 2013 A1
20130324823 Koski et al. Dec 2013 A1
20140005499 Catt et al. Jan 2014 A1
20140012511 Mensinger et al. Jan 2014 A1
20140046160 Terashima et al. Feb 2014 A1
20140088392 Bernstein et al. Mar 2014 A1
20140266785 Miller et al. Sep 2014 A1
20140313052 Yarger et al. Oct 2014 A1
20140379273 Petisce et al. Dec 2014 A1
20150123810 Hernandez-Rosas et al. May 2015 A1
20150141770 Rastogi et al. May 2015 A1
20150205947 Berman et al. Jul 2015 A1
20150207796 Love et al. Jul 2015 A1
20150241407 Ou et al. Aug 2015 A1
20160245791 Hayter et al. Aug 2016 A1
20160302701 Bhavaraju et al. Oct 2016 A1
20160317069 Hayter et al. Nov 2016 A1
20170053084 McMahon et al. Feb 2017 A1
20170185748 Budiman et al. Jun 2017 A1
Foreign Referenced Citations (57)
Number Date Country
0098592 Jan 1984 EP
0127958 Dec 1984 EP
0320109 Jun 1989 EP
0353328 Feb 1990 EP
0390390 Oct 1990 EP
0396788 Nov 1990 EP
0286118 Jan 1995 EP
1048264 Nov 2000 EP
1568309 Aug 2005 EP
3 210 137 Mar 2021 EP
2914159 Apr 2021 EP
3 831 282 Mar 2022 EP
2939158 Mar 2022 EP
4 070 727 Oct 2022 EP
4 070 727 Jul 2023 EP
3988471 Jul 2023 EP
WO-1993006237 Apr 1993 WO
WO-1996025089 Aug 1996 WO
WO-1996035370 Nov 1996 WO
WO-1998035053 Aug 1998 WO
WO-1999056613 Nov 1999 WO
WO-2000049940 Aug 2000 WO
WO-2000059370 Oct 2000 WO
WO 0078213 Dec 2000 WO
WO-2000074753 Dec 2000 WO
WO-2000078992 Dec 2000 WO
WO-2001052935 Jul 2001 WO
WO-2001054753 Aug 2001 WO
WO-2002016905 Feb 2002 WO
WO-2002058537 Aug 2002 WO
WO-2003076893 Sep 2003 WO
WO-2003082091 Oct 2003 WO
WO-2003085372 Oct 2003 WO
WO 2004006982 Jan 2004 WO
WO-2004047445 Jun 2004 WO
WO-2004061420 Jul 2004 WO
WO-2005010756 Feb 2005 WO
WO-2005040404 May 2005 WO
WO 2005065538 Jul 2005 WO
WO-2005089103 Sep 2005 WO
WO 2005121785 Dec 2005 WO
WO-2006024671 Mar 2006 WO
WO-2006051466 May 2006 WO
WO-2006064397 Jun 2006 WO
WO 2006079867 Aug 2006 WO
WO-2007007459 Jan 2007 WO
WO-2007097754 Aug 2007 WO
WO-2008086541 Jul 2008 WO
WO 2009136372 Nov 2009 WO
WO-2010022387 Feb 2010 WO
WO-2010077329 Jul 2010 WO
WO 2011026053 Mar 2011 WO
WO 2012154286 Nov 2012 WO
WO 2014070456 May 2014 WO
WO 2014105631 Jul 2014 WO
WO 2015069797 May 2015 WO
WO 2016092448 Jun 2016 WO
Non-Patent Literature Citations (370)
Entry
Exhibit CP-2, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Sparacino, et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, IEEE Transactions on Biomedical Engineering, vol. 54, No. 5, pp. 931-937 (2007).
Exhibit CP-3, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: In Vivo Glucose Sensing, Chemical Analysis, a Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley (2010).
Exhibit CP-4, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Animas® Vibe™, the First Integrated Offering from Animas Corporation and Dexcom, Inc., Receives European CE Mark Approval (2011).
Exhibit CP-6, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Bailey, et al., Reduction in Hemoglobin A1c with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study, Diabetes Technology & Therapeutics, vol. 9, No. 3, pp. 203-210 (2007).
Exhibit CP-7, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Improvement in Glycemic Excusions With a Transcutaneous, Real-Time Continuous Glucose Sensor, Diabetes Care, vol. 29, No. 1, pp. 44-50 (2006).
Exhibit CP-8, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Relatioship of Fasting and Hourly Blood Glucose Levels to HbA1c Values, Diabetes Care, vol. 29, No. 12, pp. 2644-2649 (2006).
Exhibit CP-9, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Welcome to Your FreeStyle Libre System, In-Service Guide, Abbott (2017).
Exhibit CP-10, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Standards of Medical Care in Diabetes—2009, American Diabetes Association, Diabetes Care, vol. 32, Supplement 1, pp. S13-S61 (2009).
Exhibit No. 2, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus, EMEA, The European Agency for the Evaluation of Medicinal Products (2002).
Exhibit No. 3, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Defining and Reporting Hypoglycemia in Diabetes, Diabetes Care, vol. 28, No. 5, pp. 1245-1249 (2005).
Exhibit No. 4, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Amiel, et al., Review Article, Hypoglycaemia in Type 2 diabetes, Diabetic Medicine, vol. 25, pp. 245-254 (2008).
Exhibit No. 5, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Swinnen, et al., Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia, Diabetologia, vol. 52, pp. 38-41.
Exhibit No. 6, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Frier, Defining hypoglycaemia: what level has clinical relevance?, Diabetologia, vol. 52, pp. 31-34 (2009).
Exhibit No. 7, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Cryer, Preventing hypoglycaemia: what is the appropriate glucose alert value?, Diabetologia, vol. 52, pp. 35-37 (2009).
Exhibit No. 8, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011).
Exhibit No. 9, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, European Medicines Agency, Science Medicines Health (2012).
Exhibit No. 10, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 Diabetes Research Roadmap, Identifying the strengths and weaknesses, gaps and opportunities of UK type 1 diabetes research; clearing a path to the cure, JDRF Improving Lives. Curing Type 1 Diabetes. Join us in finding the cure for type 1 diabetes (2013).
Exhibit No. 11, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, The New England Journal of Medicine, vol. 329, No. 14 (1993).
Exhibit No. 12, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Modern Standards and Service Models, Diabetes, National Service Framework for Diabetes: Standards, Department of Health (2000).
Exhibit No. 13, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Training in flexible, intensive, insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ, vol. 325 (2002).
Exhibit No. 14, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults, Clinical Guideline 15, NHS, National Institute for Clinical Excellence (2004).
Exhibit No. 15, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011).
Exhibit No. 16, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Pickup, et al., Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data, BMJ (2011).
Exhibit No. 17, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Diabetes (type 1), NIHR (2011).
Exhibit No. 18, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Aleppo, et al., REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes, Diabetes Care, vol. 40, pp. 538-545 (2017).
Exhibit No. 19, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol. 40, pp. 155-157 (2017).
Exhibit No. 20, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Continuous Glucose Sensors: Continuing Questions about Clinical Accuracy, J Diabetes Sci Technol vol. 1, Issue 5, pp. 669-675 (2007).
Exhibit No. 21, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: DeVries, Glucose Sensing Issues for the Artificial Pancreas, Journal of Diabetes Science and Technology, vol. 2, Issue 4, pp. 732-734 (2008).
Exhibit No. 22, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Innovation Milestones, et al.
Exhibit No. 23, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® System Gold™ Continuous Glucose Monitoring Overview, Medtronic MiniMed (2004).
Exhibit No. 24, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: GlucoWatch G2, Automatic Glucose Biographer and Auto Sensors (2002).
Exhibit No. 25, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guardian® REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed (2006).
Exhibit No. 26, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS° iPro™ Continuous Glucose Recorder, User Guide, Medtronic MiniMed (2007).
Exhibit No. 27, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator, Continuous Glucose Monitoring System, User Guide, Abbott (2008, 2010).
Exhibit No. 28, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator II, Continuous Glucose Monitoring System, User's Manual, Abbott (2011-2013).
Exhibit No. 29, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Dexcom G4, Continuous Glucose Monitoring System, User's Guide (2013).
Exhibit No. 30, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for US 2007/208244A1.
Exhibit No. 31, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for EP625.
Exhibit No. 32, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Puhr, et al., Real-World Hypoglycemia Avoidance with a Predictive Low Glucose Alert Does Not Depend on Frequent Screen Views, Journal of Diabetes Science and Technology, vol. 14(1), pp. 83-86 (2020).
Exhibit No. 33, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Rilstone, et al., The impact of CGM with a predictive hypoglycaemia alert function on hypoglycaemia in physical activity for people with type 1 diabetes: PACE study (2022).
Exhibit No. 34, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 2, Flash Glucose Monitoring System, User's Manual, Abbott (2019-2021).
Exhibit No. 35, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 3, Continuous Glucose Monitoring System, User's Manual, Abbott (2022).
Exhibit No. 37, to the Second Expert Report of Professor Nick Oliver, Oct. 21, 2022: Oliver, et al., Review Article, Glucose sensors, a review of current and emerging technology, Diabetic Medicine, vol. 26, pp. 197-210 (2009).
Abbott's Continuous Blood Glucose Monitor Approval Soon, 3 pages (2006).
About Dexcom—Continuous Glucose Monitoring Company, 12 pages (2021)
About the Congressional Record, Congress.gov, Library of Congress, 3 pages.
Amendment No. 2 to the OUS Commercialization Agreement, 12 pages (2011).
Anzhsn National Horizon Scanning Unit Horizon Scanning Report, GlucoWatch® G2 Biographer for the non-invasive monitoring of glucose levels, AHTA, 46 pages (2004).
Bindra, D.S., et al., Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring, Analytical Chemistry, vol. 63, No. 17, pp. 1692-1696 (1991).
Bode, B., et al., Alarms Based on Real-Time Sensor Glucose Values Alert Patients to Hypo- and Hyperglycemia: The Guardian Continuous Monitoring System, Diabetes Technology & Therapeutics, vol. 6, No. 2, pp. 105-113 (2004).
Brown, A., et al., test drive—Dexcom's G4 Platinum CGM, diatribe Learn, 4 pages (2012).
Buckingham, B., et al., Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension, Diabetes Care, vol. 33, No. 5, pp. 1013-1017 (2010).
Burton, H.D., Urging FDA to Act Promptly to Approve Artificial Pancreas Technologies, Congressional Record (Bound Edition), vol. 157, Part 13, 3 pages (2011).
Children with Diabetes, Report from Diabetes Technology Meeting, 3 pages (2003).
Choudhary, P., et al., Insulin Pump Therapy with Automated Insulin Suspension in Response to Hypoglycemia, Reduction in nocturnal hypoglycemia in those at greatest risk, Diabetes Care, vol. 34, pp. 2023-2025 (2011).
Claims, Specification and Drawings for System and Methods for Providing Sensitive and Specific Alarms, 103 pages.
Clarke, W., et al., Statistical Tools to Analyze Continuous Glucose Monitor Data, Diabetes Technology & Therapeutics, vol. 11, Supplement 1, pp. S-45-S-54 (2009).
Clemens, a.H., et al., Development of the Biostator® Glucose Clamp Algorithm, Artificial Systems for Insulin Delivery, edited by Brunetti, P., et al., Serono Symposia Publications from Raven Press, vol. 6, 13 pages (1983).
Close, K., Test Driving Dexcom's Short-Term Sensor (STS): A Look at Continuous Glucose Monitoring, diaTribe Learn, 2 pages (2006).
Continuous Glucose Monitoring (CGM)/Real-Time Flash Glucose Scanning (FGS) Training for Healthcare Professionals and Patients, Association of Children's Diabetes Clinicians, 50 pages (2017).
Cunningham, D.D., et al., In Vivo Glucose Sensing, Chemical Analysis: A Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley, 466 pages (2010).
Declaration of Dr. David Rodbard in Support of Petition for Inter Partes Review of Claims 1-5, 12, 19 and 23 of U.S. Pat. No. 10,702,215, Inter Partes Review No. IPR2022-00909 (2022).
Declaration of Duncan Hall (2021) including DexCom™ STS™ Continuous Glucose Monitoring System User's Guide (2006), 64 pages.
Dexcom Request for Confidentiality for FCC ID: PH29433, 1 page (2010).
DexCom™ STS™ Continuous Glucose Monitoring System User's Guide, 57 pages (2006).
Diabetes Close Up—Conferences—#2—Diabetes Technology, 8 pages (2003).
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System, ClinicalTrials.gov, 4 pages (2010).
Facchinetti, A, et al., A New Index to Optimally Design and Compare Continuous Glucose Monitoring Glucose Prediction Algorithms, Diabetes Technology & Therapeutics, vol. 13, No. 2, pp. 111-119 (2011).
FDA PMA Approvals, 3 pages.
FDA Premarket Approval (PMA) for Biostator GCIIS, PMA No. P790028, 3 pages, Notice Date: Feb. 20, 1981.
Feature Analysis, 1 page.
Federal Register, vol. 76, No. 120, pp. 36542-36543 (2011).
Federal Register, vol. 86, No. 211, pp. 60827-60829 (2021).
Fogt, E.J., et al., Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator®), Clinical Chemistry, vol. 24, No. 8, pp. 1366-1372 (1978).
FreeStyle Navigator® Continuous Glucose Monitoring System, User's Guide, Abbott, 196 pages (2008).
FreeStyle Navigator® Continuous Glucose Monitoring System, User's Guide, Abbott, 38 pages.
Garg, S.K., et al., Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults with Type 1 Diabetes, Diabetes Care, vol. 27, No. 3, pp. 734-738 (2004).
Glucowatch G2, Automatic Glucose Biographer and Auto Sensors, 70 pages (2002).
Glucowatch® G2™ Biographer (GW2B) Alarm Reliability During Hypoglycemia in Children, Diabetes Technol Ther, 6(5), 12 pages (2004).
Gross, T.M, et al., Performance Evaluation of the MiniMed® Continuous Glucose Monitoring System During Patient Home Use, Diabetes Technology & Therapeutics, vol. 2, No. 1, pp. 49-56 (2000).
Grounds of Invalidity amended pursuant to CPR17.1(2)(a), Claim No. HP-2021-000025, 17 pages (2022).
Guerra, S., et al., A Dynamic Risk Measure from Continuous Glucose Monitoring Data, Diabetes Technology & Therapeutics, vol. 13, No. 8, pp. 843-852 (2011).
Hayter, P.G. et al., Performance Standards for Continuous Glucose Monitors, Diabetes Technology & Therapeutics, vol. 7, No. 5, pp. 721-726 (2005).
Heinemann, L., et al., Glucose Clamps with the Biostator: A Critical Reappraisal, Horm. Metab. Res., 26, pp. 579-583 (1994).
Heller, A., et al., Electrochemical Glucose Sensors and Their Applications in Diabetes Management, Chemical Reviews, vol. 108, No. 7, pp. 2482-2505 (2008).
Heller, A., et al., Electrochemistry in Diabetes Management, Accounts of Chemical Research, vol. 43, No. 7, pp. 963-973 (2010).
Heller, A., Integrated Medical Feedback Systems for Drug Delivery, AIChE Journal, vol. 51, No. 4, pp. 1054-1066 (2005).
Hermanns, N., et al., The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose Values and Low Blood Glucose Values Assessed by Point-of-care Blood Glucose Meters: Results of a Crossover Trial, Journal of Diabetes Science and Technology, vol. 8(3), pp. 516-522 (2014).
Instructions for Use Dexcom™ STS™ Sensor, 51 pages (2006).
International Standard, IEC 60601-1-8, Medical Electrical Equipment, 166 pages (2006).
Javanmardi, C.A., et al., G4 Platinum Continuous Glucose Monitor, U.S. Pharmacist, 38(9), 8 pages (2013).
Kovatchev, B.P., et al., Assessment of Risk for Severe Hypoglycemia Among Adults with IDDM, Validation of the low blood glucose index, Diabetes Care, vol. 21, No. 11, 7 pages (1998).
Kovatchev, B.P., et al., Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors, Continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data, Diabetes Care, vol. 27, No. 8, pp. 1922-1928 (2004).
Kovatchev, B.P., et al., Risk Analysis of Blood Glucose Data: A Quantitative Approach to Optimizing the Control of Insulin Dependent Diabetes, Journal of Theoretical Medicine, vol. 3, 11 Pages (2000).
Kovatchev, B.P., et al., Symmetrization of the Blood Glucose Measurement Scale and Its Applications, Diabetes Care, vol. 20, No. 11, pp. 1655-1658 (1997).
Letter from Department of Health & Human Services re. FreeStyle Navigator Continuous Glucose Monitoring System, 7 pages (2008).
Letter from Department of Health & Human Services re. MiniMed Continuous Glucose Monitoring System, 7 pages (1999).
Letter to EPO re. Divisional Application of EP Application No. 13784079.9 in the name of Dexcom, Inc., 2 pages (2020).
Ley, T., Continuous Glucose Monitoring: A Movie is Worth a Thousand Pictures, a Review of the Medtronic Guardian REAL-time system, 3 pages.
McMurry, J.F., The Artificial Pancreas Today, Henry Ford Hospital Medical Journal, vol. 31, No. 2, Article 4, 8 pages (1983).
Medtronic User Guide, Guardian® Real-Time Continuous Glucose Monitoring System, 184 pages (2006).
MiniMed® 530G System User Guide, Medtronic, 317 pages (2012).
Original Premarket Approval Application, FreeStyle Navigator Continuous Glucose Monitoring System, Section VII: Manufacturing Section, Steven Label Sensor Sheet, Validation Plan, vol. 28 of 31, TheraSense, Inc., 61 pages (2005).
OUS Commercialization Agreement, Exhibit 10.2, 49 pages (2009).
Palerm, C.C., et al., Hypoglycemia Detection and Prediction Using Continuous Glucose Monitoring—A Study on Hypoglycemic Clamp Data, Journal of Diabetes Science and Technology. vol. 1, Issue 5, pp. 624-629 (2007).
Premarket Approval Application Amendment, FreeStyle Navigator Continuous Glucose Monitoring System, vol. 2 of 39, Section III, Device Description, Abbott Diabetes Care, Inc., 89 pages (2006).
Press Release Details, DexCom Receives FDA Approval for STS™ Continuous Glucose Monitoring System, 3 pages (2006).
Rodbard, D., A Semilogarithmic Scale for Glucose Provides a Balanced View of Hyperglycemia and Hypoglycemia, Journal of Diabetes Science and Technology, vol. 3, Issue 6, pp. 1395-1401 (2009).
Sandham, W., et al., Blood Glucose Prediction for Diabetes Therapy Using a Recurrent Artificial Neural Network, 4 pages.
Sparacino, G., et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, IEEE Transaction on Biomedical Engineering, vol. 54, No. 5, pp. 931-937 (2007).
STS® Seven Continuous Glucose Monitoring System, User's Guide, 74 pages (2007).
Summary of Safety and Effectiveness Data for Continuous Glucose Monitor, 27 pages (2008).
Summary of Safety and Effectiveness Data for DexCom™ STS™ Continuous Glucose Monitoring System, 20 pages (2006).
Summary of Safety and Effectiveness Data for STS®-7 Continuous Glucose Monitoring System, 14 pages (2007).
The CGM Resource Center References/Bibliography, 14 pages.
The Dexcom Seven Plus Quick Start Guide, 2 pages (2010).
TheraSense Files Premarket Approval Application for Freestyle Navigator(TM) Cont, 3 pages (2003).
TheraSense Navigates Continuous Glucose Monitor PMA, Prepares for Flash, The Gray Sheet, vol. 29, No. 37, 2 pages (2003).
U.S. Food & Drug Administration, Premarket Approval (PMA) for Continuous Glucose Monitoring System, PMA No. P980022, 20 pages, Notice Date: Jul. 14, 1999.
U.S. Food & Drug Administration, Premarket Approval (PMA) for Dexcom Seven Plus System, PMA No. P050012, 3 pages.
U.S. Food & Drug Administration, Premarket Approval (PMA) for Dexcom STS Continuous Monitors, PMA No. P050012, 8 pages, Notice Date: May 12, 2006.
U.S. Food & Drug Administration, Premarket Approval (PMA) for Freestyle Navigator Continuous Glucose Monitor, PMA No. P050020, 6 pages, Notice Date: Apr. 1, 2008.
United States Securities and Exchange Commission, Form 10-K, Dexcom, Inc., 55 pages (2006).
United States Securities and Exchange Commission, Form 10-K, Dexcom, Inc., 59 pages (2005).
United States Securities and Exchange Commission, Form S-1, Dexcom, Inc., 309 pages (2005).
Williams, S., et al., The Guardian REAL-Time Continuous Glucose Monitoring System, U.S. Pharmacist, 32(12), 16 pages (2007).
U.S. Appl. No. 13/684,078 (U.S. Pat. No. 8,710,993), filed Nov. 21, 2012 (Apr. 29, 2014).
U.S. Appl. No. 14/251,542 (U.S. Pat. No. 9,289,179), filed Apr. 10, 2014 (Mar. 22, 2016).
U.S. Appl. No. 15/016,247 (U.S. Pat. No. 9,743,872), filed Feb. 4, 2016 (Aug. 29, 2017).
U.S. Appl. No. 15/686,153 (U.S. Pat. No. 10,136,847), filed Aug. 23, 2017 (Nov. 27, 2018).
U.S. Appl. No. 16/197,253 (U.S. Pat. No. 10,939,859), filed Nov. 20, 2018 (Mar. 9, 2021).
U.S. Appl. No. 13/684,078, Mar. 7, 2014 Issue Fee Payment.
U.S. Appl. No. 13/684,078, Feb. 14, 2014 Notice of Allowance.
U.S. Appl. No. 13/684,078, Dec. 31, 2013 Response to Non-Final Office Action.
U.S. Appl. No. 13/684,078, Dec. 27, 2013 Non-Final Office Action.
U.S. Appl. No. 14/251,542, Feb. 10, 2016 Issue Fee Payment.
U.S. Appl. No. 14/251,542, Nov. 25, 2015 Notice of Allowance.
U.S. Appl. No. 14/251,542, Oct. 30, 2015 Response to Non-Final Office Action with Terminal Disclaimer.
U.S. Appl. No. 14/251,542, Sep. 25, 2015 Non-Final Office Action.
U.S. Appl. No. 15/016,247, Jul. 21, 2017 Issue Fee Payment.
U.S. Appl. No. 15/016,247, Jun. 15, 2017 Notice of Allowance.
U.S. Appl. No. 15/016,247, Feb. 1, 2017 Terminal Disclaimer.
U.S. Appl. No. 15/016,247, Dec. 13, 2016 Final Office Action.
U.S. Appl. No. 15/016,247, Sep. 6, 2016 Response to Non-Final Office Action.
U.S. Appl. No. 15/016,247, Jun. 17, 2016 Non-Final Office Action.
U.S. Appl. No. 15/686,153, Oct. 20, 2018 Issue Fee Payment.
U.S. Appl. No. 15/686,153, Aug. 7, 2018 Notice of Allowance.
U.S. Appl. No. 15/686,153, Jun. 14, 2018 Response to Final Office Action with Terminal Disclaimer.
U.S. Appl. No. 15/686,153, Jun. 13, 2018 Final Office Action.
U.S. Appl. No. 15/686,153, Feb. 20, 2018 Response to Non-Final Office Action.
U.S. Appl. No. 15/686,153, Sep. 22, 2017 Non-Final Office Action.
U.S. Appl. No. 16/197,253, Jan. 28, 2021 Issue Fee Payment.
U.S. Appl. No. 16/197,253, Oct. 28, 2020 Notice of Allowance.
U.S. Appl. No. 16/197,253, Aug. 14, 2020 Response to Final Office Action with Terminal Disclaimer.
U.S. Appl. No. 16/197,253, Jun. 29, 2020 Final Office Action.
U.S. Appl. No. 16/197,253, Apr. 10, 2020 Response to Non-Final Office Action.
U.S. Appl. No. 16/197,253, Jan. 10, 2020 Non-Final Office Action.
Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526.
Arnold, M. A., et al., “Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors”, Journal of Diabetes Science and Technology, vol. 1, No. 4, 2007, pp. 454-462.
Aussedat, B., et al., “A User-Friendly Method for Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycemic Alarm”, Biosensors & Bioelectronics, vol. 12, No. 11, 1997, pp. 1061-1070.
Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25-33.
Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.
Boyne, M. S., et al., “Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor”, Diabetes, vol. 52, Nov. 2003, pp. 2790-2794.
Bremer, T. M., et al., “Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 409-418.
Brooks, S. L., et al., “Development of an On-Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/88, pp. 45-56.
Cass, A. E., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56, No. 4, 1984, 667-671.
Cheyne, E. H., et al., “Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers”, Diabetes Technology & Therapeutics, vol. 4, No. 5, 2002, pp. 607-613.
Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244.
El-Khatib, F. H, et al., “Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine”, Journal of Diabetes Science and Technology, vol. 1, No. 2, 2007, pp. 181-192.
Eren-Oruklu, M., et al., “Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models”, Diabetes Technology & Therapeutics vol. 11(4), 2009, pp. 243-253.
Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769-779.
Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004, pp. 1.
Garg, S., et al., “Improvement in Glycemic Excursions with a Transcutaneous, Real-Time Continuous Glucose Sensor”, Diabetes Care, vol. 29, No. 1, 2006, pp. 44-50.
Hovorka, R., et al., “Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes”, Physiological Measurement, vol. 55, Jul. 2004, pp. 905-920.
Isermann, R., “Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639-652.
Isermann, R., et al., “Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709-719.
Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.
Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, 2002, pp. 250.
Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304.
Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.
Kovatchev, B. P., et al., “Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag”, Diabetes Technology & Therapeutics, vol. 11, No. 3, 2009, pp. 139-143.
Kuure-Kinsey, M., et al., “A Dual-Rate Kalman Filter for Continuous Glucose Monitoring”, Proceedings of the 28th IEEE, EMBS Annual International Conference, New York City, 2006, pp. 63-66.
Li, Y., et al., “In Vivo Release From a Drug Delivery MEMS Device”, Journal of Controlled Release, vol. 100, 2004, pp. 211-219.
Lo, B., et al., “Key Technical Challenges and Current Implementations of Body Sensor Networks”, Body Sensor Networks, 2005, pp. 1-5.
Lodwig, V., et al., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 573-587.
Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74.
Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658.
McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 2001, 16 Pages.
McGarraugh, G., et al., “Physiological Influences on Off-Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376.
McKean, B. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532.
Morbiducci, U, et al., “Improved Usability of the Minimal Model of Insulin Sensitivity Based on an Automated Approach and Genetic Algorithms for Parameter Estimation”, Clinical Science, vol. 112, 2007, pp. 257-263.
Mougiakakou, et al., “A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients”, Proceedings of the 2005 IEEE, 2005, pp. 298-301.
Panteleon, A. E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration”, Diabetes Technology & Therapeutics, vol. 5, No. 3, 2003, pp. 401-410.
Parker, R., et al., “Robust H∞ Glucose Control in Diabetes Using a Physiological Model”, AIChE Journal, vol. 46, No. 12, 2000, pp. 2537-2549.
Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/88, pp. 335-346.
Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213-217.
Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272.
Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors”, The American Physiological Society, 1995, E155-E161.
Rodriguez, N., et al., “Flexible Communication and Control Protocol for Injectable Neuromuscular Interfaces”, IEEE Transactions on Biomedical Circuits and Systems, vol. 1 No. 1, 2007, pp. 19-27.
Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241.
Sakakida, M., et al., “Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158.
Sakakida, M., et al., “Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322.
Salehi, C., et al., “A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308.
Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299.
Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406.
Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313.
Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210.
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301.
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor”, The Lancet, 1982, pp. 1129-1131.
Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942.
Steil, G. M., et al., “Closed-Loop Insulin Delivery—the Path of Physiological Glucose Control”, Advanced Drug Delivery Reviews, vol. 56, 2004, pp. 125-144.
Steil, G. M., et al., “Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor”, Diabetes Technology & Therapeutics, vol. 5, No. 1, 2003, pp. 27-31.
Sternberg, R., et al., “Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40.
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261.
Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115.
Updike, S. J., et al., “Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117-137.
Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964.
Wilson, G. S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617.
U.S. Appl. No. 13/684,078, Notice of Allowance dated Feb. 14, 2014.
U.S. Appl. No. 13/684,078, Office Action dated Dec. 27, 2013.
U.S. Appl. No. 14/251,542, Notice of Allowance dated Nov. 25, 2015.
U.S. Appl. No. 14/251,542, Office Action dated Sep. 25, 2015.
U.S. Appl. No. 15/016,247, Notice of Allowance dated Jun. 15, 2017.
U.S. Appl. No. 15/016,247, Office Action dated Dec. 13, 2016.
U.S. Appl. No. 15/016,247, Office Action dated Jun. 17, 2016.
U.S. Appl. No. 15/686,153, Notice of Allowance dated Aug. 7, 2018.
U.S. Appl. No. 15/686,153, Office Action dated Jun. 13, 2018.
U.S. Appl. No. 15/686,153, Office Action dated Sep. 22, 2017.
U.S. Appl. No. 16/197,253 (U.S. Pat. No. 10,939,859), Nov. 20, 2018 (Mar. 9, 2021).
“DexCom's 7-Day STS Continuous Glucose Monitoring System”, Jun. 1, 2007 https://newatlas.com/dexcoms-7-day-sts-continuous-glueose-monitoring-system/7376/ 1 page.
Guardian® REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed, Inc., 181 pages (2006).
Kamath et al., “Methods of Evaluating the Utility of Continuous Glucose Monitor Alerts,” Journal of Diabetes Science and Technology, 4(1):57-66 (2010).
Alva et al., “Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System with Advanced Algorithm in Pediatric and Adult Population with Diabetes,” Journal of Diabetes Science and Technology, vol. 16(1) 70-77 (2022).
Campbell et al., “Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study,” Pediatric Diabetes, 1294-1301 (2018).
Deshmukh et al., “Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit,” https://doi.org/10.2337/dc20-0738, Diabetes Care, 8 pages (2020).
Deutscher Gesundheitsbericht, Diabetes 2021, Die Bestandsaufnahme , German Diabetes Society, with English Abstract, 15 pages (2021).
FDA, STS-7 Continuous Glucose Monitoring System, P050012/S001, May 31, 2007, 95 pages.
Haak et al., “Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes,” Diabetes Ther., 14 pages (2017).
Roussel et al., “Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The Relief Study,” American Diabetes Association, Diabetes Care, 1368-1376 (2021).
File history of U.S. Appl. No. 61/551,773, filed Oct. 26, 2011.
Harvey, et al., Clinically Relevant Hypoglycemia Prediction Metrics for Event Mitigation, Diabetes Technology & Therapeutics. Vol. 14, No. 8, pp. 719-727 (2012).
Hughes, et al., Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green “Traffic” Lights Using Continuous Glucose Monitoring and Insulin Pump Data, Journal of Diabetes Science and Technology, vol. 4, Issue 5, pp. 1146-1155 (2010).
Schiavon, An online method for prevention of the risk of glycemic shock in diabetic patients from continuous glucose monitoring data, 110 pages (2010) with English translation of summary attached.
Premarket Approval Letter with Summary of Safety and Effectiveness Data for the Freestyle Navigator Continuous Glucose Monitor, Mar. 12, 2008 [ 34 pgs.].
Schiavon, A method online for there prevention of the risk of glycerine shock in diabetic patients from data of monitoring continuous of the glucose [with English translation], 220 pages (2010).
Townsend, et al., Getting Started with Bluetooth Low Energy, Tools and Techniques for Low-Power Networking, O'Reilly, 180 pages (2014).
User Guide for the Navigator Freestyle (Mar. 2008) [38 pgs.].
Wang, et al., NYIT School of Engineering and Computing Sciences, A Feasible IMD Communication Protocol: Security without Obscurity, 1 page (2015).
Ballard, “User Interface Design Guidelines for J2ME MIDP 2.0” 9 pages (2005).
U.S. Appl. No. 61/238,657, filed Aug. 31, 2009, 198 pages.
U.S. Appl. No. 61/238,657, filed Aug. 31, 2009, 60 pages.
U.S. Appl. No. 61/247,541, filed Sep. 30, 2009, 69 pages.
U.S. Appl. No. 61/297,265, filed Jan. 22, 2010, 54 pages.
Cunningham et al., Winefordner Seried Editor, “Chemical Analysis: A Seried of Monographs on Analytical Chemistry and Its Applications—In Vivo Glucose Sensing” 50 pages (2010).
Declaration of Thomas Edward Foster of Taylor Wessing LLP, Hill House, 1 Little New St. London EC4A 3TR (“Taylor Wessing”), in Relation to STS-7 User's Guide, Jan. 30, 2024, 160 pages.
DexCom STS-7 Approval Order, Department of Health and Human Services, FDA, May 31, 2007, 7 pages.
FDA Premarket Approval PMA Order for the STS-7, 3 pages, May 31, 2007.
File History of U.S. Pat. No. 10,375,222, issued Aug. 6, 2019, 442 pages.
Microsoft Applications for Windows Mobile 6 User Guide, 184 pages (2008).
NFC Forum, Bluetooth® Secure Simple Pairing Using NFC Application Document NFC Forum TM, NFCForum-AD-BTSSP_ 1_1, 2014-01-09, 39 pages.
Omre, Bluetooth Low Energy: Wireless Connectivity for Medical Monitoring, Journal of Diabetes Science and Technology, vol. 4, Issue 2, 457-463 Mar. 2010.
Padgette et al., “Guide to Bluetooth Security, Recommendations of the National Institute of Standards and Technology,” National Institute of Standards and Technology, U.S. Department of Commerce, Special Publication 800-121 Revision 1, 48 pages, May 2017.
Specification Bluetooth System Experience More, 134 pages, Jun. 2010.
Specification Bluetooth System Wireless connections, 92 pages, Nov. 2003.
Strömmer et al., “Application of Near Field Communication for Health Monitoring in Daily Life,” Proceedings of the 28th IEEE FrC09.1 EMBS Annual International Conference New York City, USA, 3246-3249, Aug. 30-Sep. 3, 2006.
Wayback Machine internet archive of US FDA CDRH PMA Final Decisions Rendered, 21 pages, May 2007.
Zhang et al., “Bluetooth Low Energy for Wearable Sensor-based Healthcare Systems,” 2014 Health Innovations and Point-of-Care Technologies Conference Seattle, Washington USA, 251-254, Oct. 8-10, 2014.
A Dictionary of Computer Science, Seventh Edition, Oxford University Press, “authentication”, 3 pages (2016).
A Dictionary of Computing, Sixth Edition, Oxford University Press, “function”, 3 pages (2008).
Ananthi, “A Text Book of Medical Instruments,” New Age International (P) Limited, Publishers, 7 pages (2005).
Annex A2 Documents relating to the Patent Extract from the EP Register for the Patent, EP 3988471, 6 pages (2023).
Annex B1 Evidence relating to infringing products Dexcom G6 Start Here Guide, 21 pages (2023).
Annex B3 User Guide LibreLinkUp, 28 pages (2023).
Annex B4 Extract from the pricacy notice for LibreView, 7 pages (2024).
Annex C1 Evidence relating to infringing acts Materials concerning supply of Dexcom's Products in France, 10 pages (2022).
Annex D1 UPC Court of Appeal Feb. 26, 2024, 335/2023, 38 pages (2024).
Annex D38 Info Technology Digest, vol. 5 Issue 5, 32 pages (1996).
Annex D39 Best Practice for Software Asset Management, 7 pages (2023).
Annex D40 Nagpal, “Computer Fundamentals, concepts, Systems and Applications,” 5 pages (2008).
Annex E3 Excerpts from the “German Health Report Diabetes 2023” of the German Diabetes Society, 23 pages (2023) with English translation.
Annex F5 Application to amend the Patent under R30 RoP, 5 pages (2024).
Annex G2 Case law of the Boards of Appeal, I.C-4.3, 3 pages (2024).
Annex G3 European Patent Guide, 23rd ed., chapter 3 (“Patentability”), 3.4, 6 pages (2023).
Annex G5 Case Law of the Boards of Appeal, I-D, 4.2.0, 2 pages (2023).
Annex G6 UPC Court of Appeal Feb. 26, 2024 NanoString Technologies v. 10x Genomics, 38 pages (2024).
Annex G7 Decision of the Enlarged Board of the EPO, G 3/14 97 pages (2015).
Annex G8 Willem Hoyng, “The Unified Patent Court (UPC) opens its doors! Some observations”, 42 pages (2023).
Annex G10 Düsseldorf Local Division Oct. 18, 2023, UPC_CFI 177 2023 (MyStromer v Revolt Zycling), 19 pages (2023).
Annex G11 Munich Local Division Apr. 23, 2024, UPC CFI 514/2023 (Volkswagen AG, Audi AG, Texas Instruments Inc. and Texas Instruments Deutschland GmbH v. Network system Technologies LLC), 10 pages (2024).
Annex G12 Munich Local Division, Sep. 19, 2023, UPC_CFI_2/2023 (NanoString Technologies v. 10x Genomics), 107 pages (2023).
Annex G13 Regulation 2017/745 (EU), 176 pages (2017).
Annex G14 P. England, ‘A Practitioner's Guide to the Unified Patent Court and Unitary Patent’, Hart Publishing 2022, p. 159, 7 pages (2022).
“Biomedical Engineering Desk Reference,” Elsevier, 5 pages (2009).
Burr et al., Electronic Authentication Guideline, NIST Special Publication 800-63-2, NIST U.S. Dept. of Commerce, Aug. 2013, 123 pages.
Cunningham, In Vivo Glucose Sensing, 9 pages (2010).
Cunningham et al., “In Vivo Glucose Sensing,” Wiley & Sons, 50 pages (2010).
Cunningham et al., “In Vivo Glucose Sensing,” Wiley & Sons, 111 pages (2010).
Cunningham et al., “In Vivo Glucose Sensing Chemical Analysis: A Series of Monographs on Analytical chemistry and Its Applications,” Wiley & Sons, 1 page (2010).
Custodio et al., “A Review on Architectures and Communications Technologies for Wearable Health-Monitoring Systems,” Sensors 12, 13907-13946 (2012).
D29 Medtronic, Paradignm REAL-Time Revel™ Minimed, Part 1 132 pages, Part 2 133 pages (2009).
Dexcom, Seven Plus CGMS Users Guide, 144 pages (2008).
D'Imporzano, Dr., “Reaching More of the World,” Johnson & Johnson Celebrating 125 Years, Annual Report 2010, 2 pages.
Ericksen et al., “Orthospinology Procedures, An Evidence-Based Approach to Spinal Care,” 6 pages (2007).
FreeStyle Navigator® CGMS Indications for Use, 96 pages (2008).
FreeStyle Navigator® CGMS Indications for Use, 196 pages (2008).
G7 User Guide, Instructions for Use, 174 pages (2024).
Hashimoto et al., “Examination of Usefulness of Color Indicator Function of OneTouch Ultra VueTM, Medicine and Pharmacy,” D44-D43, Opposition EP 3 988 471 B1, Hoffmann Elite, 9 pages (with English Translation) (2010).
Huizinga et al., “Automated Defect Prevention, Best Practices in Software Management,” 6 pages (2007).
IEEE 100 The Authoritative Dictionary of IEEE Standards Terms, Seventh Ed., “authentication”, 3 pages (2000).
Letter to Bob Shen at Dexcom, Inc. dated May 15, 2023, FDA U.S. Food & Drug Administration, 8 pages.
Medronic, The MiniMed Paradigm® Real-Time System, 8 pages (2005).
Medronic, The MiniMed Paradigm® Real-Time System, Insulin Pump and CGMS, 8 pages (2008).
Medronic, The MiniMed Paradigm® Real-Time Insulin Pump User Guide, Paradigm® 522 and 722 Insulin Pumps, 176 pages (2006).
Medronic, Guardian® Real-Time Continuous Glucose Monitoring System, User Guide, 184 pages (2006).
Medronic, The MiniMed Paradigm® Real-Time Sensor Features User Guide, Paradigm® 522 and 722 Insulin Pumps, 76 pages (2006).
Medronic, Paradigm® Real-Time. Revel™ Insulin PumpUser Guide, 132 pages (2009).
Mosa et al., “A Systematic Review of Healthcare Applications for Smartphones,” BMC Med Informatice and Secision Making, 32 pages (2012).
Motorola, Microsoft Applications for Windows Mobile 6 User Guide, 184 pages (2008).
Newton, Newton's Telecom Dictionary, 30th Upldated, Expanded, Aniversry Ed., “authenticate”, 4 pages (2016).
OneTouch Handling Instructions, For self-examination glucose meter, Part 1—36 pages, Part 2—36 pages, Part 3—36 pages (with English Translation 6 pages) (2018).
OneTouch Ultra VueTM, 3 pages (2010).
Section 7 Calibrate Your System/Test Blood Glucose Manually, 65 pages (2008).
Section 10 Response to Alarms, Errors, and Problems, 96 pages (2008).
Seven Plus continuous glucose monitoring system User's Guide, Dexcom, 72 pages (2008).
Sommerville, “Software Engineering,” 7 pages (2007).
Stone et al., “User Interface Design and Evaluation,” The Open University, 4 pages (2005).
Stone et al., “User Interface Design and Evaluation,” The Open University, 13 pages (2005).
Stone et al., “User Interface Design and Evaluation,” The Open University, 153 pages (2005).
Stoodley et al., “The Automatic Detection of Transients, Step Changes and Slope Changes in the Monitoring of Medical Time Series,” The Statistician, vol. 28 No. 3, 163-170 (1979).
Wiklund, “Medical Device and Equipment Design,” 6 pages (1995).
About the Congressional Record, Congress. Gov, 3 pages, Feb. 22, 2022.
Approved Judgment, In the High Court of Justice Business and Property Courts of England and Wales Intellectual Property List (ChD) Patents Court, Case No. HP-2021-000025 & HP-2021-000026, 137 pages, Jan. 15, 2024.
Bequette, “Continuous Glucose Monitoring: Real-Time Algorithms for Calibration, Filtering, and Alarms,” Journal of Diabetes Science and Technology, vol. 4, Issue 2, 404-418, Mar. 2010.
Breen, The iPhone Pocket Guide, Sixth Edition, Peachpit Press, 96 pages (2012).
Dassau et al., Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring, A safety net for the artificial pancreas, Diabetes Care, vol. 33, No. 3, 1249-1254 (2010).
Declaration of Dr. Sayfe Kiael, Ph.D., Inter Partes Review of U.S. Pat. No. 10,375,222, 100 pages (2024).
Declaration of David Rodbard, M.D., Petition for Inter Partes Review of U.S. Pat. No. 9,119,528, IPR2024-00840, 109 pages, May 1, 2024.
Declaration of Lane Desborough, Petition for Inter Partes Review of U.S. Pat. No. 11,213,204, IPR2024-00853, 150 pages, May 3, 2024.
Declaration of Sylvia D. Hall-Ellis, Ph.D., IPR2024-00840 of U.S. Pat. No. 9,119,528, Parts 1-2 (400 pages) Apr. 24, 2024.
Department of Health & Human Services, FDA, P050012/S001, STS-7 Continuous Glucose Monitoring System, 7 pages, May 31, 2007.
Desalvo et al., “Remote Glucose Monitoring in Camp Setting Reduces the Risk of Prolonged Nocturnal Hypoglycemia,” Diabetes Technology & Therapeutics, vol. 16, No. 1, 10 pages, DOI: 10.1089/dia.2013.0139 (2014).
Dexcom, Leading the Way for You & Your Patients with Continuous Glucose Monitoring, 12 pages (2010).
FDA [Docket No. FDA-2011-D-0464], Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption and Premarket Approval Applications for Low Glucose Suspend Device Systems; Availability, Federal Register / vol. 76, No. 120 / Wednesday, Jun. 22, 2011 /Notices, 2 pages.
FDA PMAa Final Decisions Rendered for May 2007—The Wayback Machine—https://web.archive.org/web/20070630150626/http:/www.fda.gov/cdrh/pma/pmamay07.html, 21 pages, Jun. 13, 2007.
FDA STS-7, Glucose Monitoring System—P050012/S001, The Wayback Machine—https://web.archive.org/web/20070705190828/http:/www.fda.gov:80/cdrh/pdf5/p050012s001.html, 1 page, 2007.
FDA FreeStyle Navigator Continuous Glucose Monitoring System, P050020, 7 pages, Mar. 12, 2008.
File History of U.S. Pat. No. 9,801,541 issued Oct. 31, 2017, 834 pages.
Keith-Hynes et al., “The Diabetes Assistant: A Smartphone-Based System for Real-Time Control of Blood Glucose,” Electronics, 3, 609-623; doi:10.3390/electronics3040609 (2014).
Klonoff et al., “Innovations in Technology for the Treatment of Diabetes: Clinical Development of the Artificial Pancreas (an Autonomous System),” Journal of Diabetes Science and Technology, vol. 5, Issue 3, 804-826, May 2011.
Kowalski, “Can We Really Close the Loop and How Soon? Accelerating the Availability of an Artificial Pancreas: A Roadmap to Better Diabetes Outcomes,” Diabetes Technology & Therapeutics, vol. 11, Suppl 1, DOI: 10.1089/dia.2009.0031, S-113-S-119, 10 pages (2009).
Ley, “Continuous Glucose Monitoring: A Movie is Worth a Thousand Pictures A Review of the Medtronic Guardian Real-time system,” https://nfb.org/images/nfb/publications/vod/vod 22 4/vodfal0702.htm, 3 pages (2021).
McDaniel et al., “Remote Management of Cardiac Patients, The Forefront of a New Standard,” Modern Healthcare, 6 pages, Nov. 14, 2011.
Murphy et al., “Closed-Loop Insulin Delivery During Pregnancy complicated by Type 1 Diabetes,” Emerging Treatments and Technologies, Diabetes Care, vol. 34, 406-411 (2011).
MySentry™ User Guide, Medronic Minimed, 80 pages (2010).
Padgette et al., “Guide to Bluetooth Security, Recommendations of the National Institute of Standards and Technology,” NET Special Publication 800421 Revision National Institute of Standards and Technology, U.S. Department of Commerce, 48 pages (2012).
Palerm et al., “Hypoglycemia Prediction and Detection Using Optimal Estimation,” Diabetes Technology & Therapeutics, vol. 7, No. 1, 12 pages (2005).
Pickup, “Semi-Closed-Loop Insulin Delivery Systems: Early Experience with Low-Glucose Insulin Suspend Pumps,” Diabetes Technology & Therapeutics, vol. 13, No. 7, DOI: 10.1089/dia.2011.0103, 695-698 (2011).
Place et al., “DiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas Outpatient Trials,” Journal of Diabetes Science and Technology vol. 7, Issue 6, 1427-1435 (2013).
Scheduling Order, Abbott Diabetes Care Inc v. Dexcom, Inc., C.A. No. 23-239 (KAJ), 14 pages, Sep. 19, 2023.
Schiavon, “A method online For there prevention of the risk of glycerine shock in diabetic patients from data Of rmonitoring continuous of the glucose ,” Thesis (with English translation) 219 p. Apr. 20, 2010.
Steil et al., “Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes,” Diabetes, vol. 55, 3344-3350 (2006).
The Diabetes Research in Children Network (DirecNet) Study Group, “GlucoWatch® G2TM Biographer (GW2B) Alarm Reliability During Hypoglycemia in Children*,” Diabetes Technol Ther., 6(5): 559-566 (2004).
Weinstein et al., “Diabetes Care, ADA 2006: Spotlight on Continuous Glucose Monitoring,” JP Morgan, North America Equity Research, 16 pages, Jun. 11, 2006.
Weinzimer et al., “Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients with Type 1 Diabetes Using an Artificial Pancreas,” Emerging Treatments and Technologies, Diabetes Care, vol. 31, No. 5, 934-939 (2008).
Wettlaufer, “merlin.net Automation of External Reports Verification Process,” A Thesis Presented to The Faculty of California Polytechnic State University, San Luis Obispo, 53 pages, Jan. 2010.
Wilson et al., “Introduction to the Glucose Sensing Problem,” In Vivo Glucose Sensing, Edited by D. D. Cunningham and J. A. Stenken, Wiley & Sons, Inc., 27 pages, (2010).
Wright et al., “Continuous Glucose Monitoring (CGM)/Real-Time Flash Glucose Scanning (FGS) Training for Healthcare Professionals and Patients,” Association of Children's Diabetes Clinicians, 50 pages (2017).
Select pages from OneTouch Ultra Vue User Manual published on Oct. 1, 2009 (with English Translation), 4 pages.
Related Publications (1)
Number Date Country
20210196156 A1 Jul 2021 US
Provisional Applications (1)
Number Date Country
61563518 Nov 2011 US
Continuations (5)
Number Date Country
Parent 16197253 Nov 2018 US
Child 17179635 US
Parent 15686153 Aug 2017 US
Child 16197253 US
Parent 15016247 Feb 2016 US
Child 15686153 US
Parent 14251542 Apr 2014 US
Child 15016247 US
Parent 13684078 Nov 2012 US
Child 14251542 US